nct_id stringlengths 11 11 | title stringlengths 23 300 | phase stringclasses 9
values | status stringclasses 13
values | study_type stringclasses 2
values | is_expanded_access bool 2
classes | sponsor stringlengths 5 100 | summary stringlengths 45 4.76k | interventions listlengths 1 12 | start_date stringlengths 0 10 | url stringlengths 44 44 | target_entities listlengths 0 5 | locations listlengths 0 104 | contact_phone stringlengths 0 29 | contact_email stringlengths 0 41 | eligibility dict | mechanism_summary dict |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NCT00690118 | Study of Pioglitazone in Patients With Amyotrophic Lateral Sclerosis | PHASE2 | TERMINATED | INTERVENTIONAL | false | University of Ulm | Primary objective:
Efficacy of pioglitazone (45 mg/day) as add-on therapy to standard therapy with riluzole in patients with ALS compared to placebo in terms of survival (mortality defined exclusively as death).
This is a prospective, multicentre, randomised, stratified, parallel-group, double-blind trial comparing p... | [
{
"type": "DRUG",
"name": "pioglitazone"
},
{
"type": "DRUG",
"name": "placebo"
}
] | 2008-05 | https://clinicaltrials.gov/study/NCT00690118 | [
"insulin_sensitivity_metabolic_dysfunction"
] | [
{
"facility": "Department of Neurology, University of Ulm",
"city": "Ulm",
"state": "Baden-Wurttemberg",
"country": "Germany",
"status": "",
"lat": 48.39841,
"lon": 9.99155
},
{
"facility": "Department of Neurology and Center for Palliative Medicine, University of Munich",
"c... | {
"criteria": "Inclusion Criteria:\n\n* possible, probable (clinically or laboratory) or definite ALS according to the revised version of the El Escorial World Federation of Neurology criteria\n* disease duration more than 6 months and less than 3 years\n* best-sitting FVC between 50% and 95% of predicted normal\n* c... | {
"compound": "pioglitazone",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT06968468 | Resiliency Intervention for Patients With ALS and Their Care-Partners | NA | NOT_YET_RECRUITING | INTERVENTIONAL | false | Massachusetts General Hospital | The purpose of this study is to pilot a resiliency and coping intervention for persons recently diagnosed with Amyotrophic Lateral Sclerosis (ALS) and their primary informal caregivers. The data investigators gather in this study will be used to further refine our intervention. | [
{
"type": "BEHAVIORAL",
"name": "Resilient Together ALS"
}
] | 2026-05-13 | https://clinicaltrials.gov/study/NCT06968468 | [] | [
{
"facility": "Massachusetts General Hospital",
"city": "Boston",
"state": "Massachusetts",
"country": "United States",
"status": "",
"lat": 42.35843,
"lon": -71.05977
}
] | 617-643-7641 | crush2@mgh.harvard.edu | {
"criteria": "Inclusion Criteria for patient with ALS:\n\n* recent (within \\~2 months) of first appointment at Healey Center for diagnosis of ALS documented in Epic (based on recommendations from neurologists)\n* ability to understand the study and research protocol as determined by a standardized teach-back method... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT03472950 | Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis | PHASE2 | COMPLETED | INTERVENTIONAL | false | University of Kansas Medical Center | The purpose of this research study is to evaluate the safety and effectiveness of Ranolazine, and how well it is tolerated in patients with Amyotrophic Lateral Sclerosis (ALS). Ranolazine is an FDA approved drug that is used for decreasing chest pain. | [
{
"type": "DRUG",
"name": "Ranolazine 500 MG"
},
{
"type": "DRUG",
"name": "Ranolazine 1000 MG"
}
] | 2018-06-11 | https://clinicaltrials.gov/study/NCT03472950 | [
"late_sodium_current_cardiac_myocyte_function"
] | [
{
"facility": "University of Kansas Medical Center",
"city": "Kansas City",
"state": "Kansas",
"country": "United States",
"status": "",
"lat": 39.11417,
"lon": -94.62746
}
] | {
"criteria": "Inclusion Criteria:\n\n* Patients with clinically definite, probable, laboratory supported probable, or possible ALS per revised El Escorial criteria\n* Cramp frequency greater than 4 cramps per week during 2 week run in\n* ALS functional rating scale-revised (ALSFRS-R) score of greater than 24\n* Able... | {
"compound": "Ranolazine",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT07118319 | The Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects With Amyotrophic Lateral Sclerosis | PHASE1 | RECRUITING | INTERVENTIONAL | false | XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. | A Phase I Study to Assess the Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects with Amyotrophic Lateral Sclerosis | [
{
"type": "DRUG",
"name": "Human Allogeneic Induced Pluripotent Stem Cells (iPSCs) -Derived Motor Neuron Progenitor Cells (XS228CN)"
},
{
"type": "DRUG",
"name": "Human Allogeneic Induced Pluripotent Stem Cells (iPSCs) -Derived Motor Neuron Progenitor Cells (XS228CN)"
}
] | 2025-09-15 | https://clinicaltrials.gov/study/NCT07118319 | [
"motor_neuron_replacement_regeneration"
] | [
{
"facility": "Peking University Third Hospital",
"city": "Beijing",
"state": "Beijing Municipality",
"country": "China",
"status": "RECRUITING",
"lat": 39.9075,
"lon": 116.39723
}
] | +86 21 64027719 | CEO@xellsmart.com | {
"criteria": "Inclusion Criteria:\n\n1. 18-75 years of age (inclusive of 18 and 75 years), regardless of gender;\n2. Diagnosed of definite or probable ALS according to the revised EI Escorial criteria;\n3. Respiratory function FVC at baseline was ≥70% of the predicted value (FVC%);\n4. Patients with birth-potential ... | {
"compound": "Human Allogeneic Induced Pluripotent Stem Cells (iPSCs)-Derived Motor Neuron Progenitor Cells (XS228CN)",
"targeting_mechanism": "Motor neuron progenitor cells to replace or support degenerating motor neurons",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": ... |
NCT02988297 | Nebulized RNS60 for the Treatment of Amyotrophic Lateral Sclerosis | PHASE2 | WITHDRAWN | INTERVENTIONAL | false | Revalesio Corporation | The purpose of this study is to determine whether nebulized RNS60 is effective in the treatment of amyotrophic lateral sclerosis (ALS). | [
{
"type": "DRUG",
"name": "RNS60"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2026-10 | https://clinicaltrials.gov/study/NCT02988297 | [
"oxidative_stress_cellular_redox_balance"
] | [] | {
"criteria": "Inclusion Criteria:\n\n* Probable, probable-laboratory supported, or definite ALS, either sporadic or familial according to modified El Escorial criteria\n* Disease duration \\< 3 years\n* Age 18 to 80\n* Able to provide informed consent and to comply with study procedures\n* Subjects must not have tak... | {
"compound": "RNS60",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT04557410 | Open Label Study: Treatment of ALS Fatigue With PolyMVA | PHASE1 | COMPLETED | INTERVENTIONAL | false | University of Missouri-Columbia | Amyotrophic lateral sclerosis (ALS) is a disease that causes the death of upper and lower motor neurons. ALS symptoms are characterized by stiffness, muscle twitching, and worsening weakness due to muscle breakdown. Onset of symptoms are typically arm or leg weakness or difficulty speaking or swallowing and gradual dev... | [
{
"type": "DRUG",
"name": "PolyMVA"
}
] | 2020-09-23 | https://clinicaltrials.gov/study/NCT04557410 | [
"mitochondrial_function_oxidative_stress"
] | [
{
"facility": "University of Missouri-Columbia School of Medicine",
"city": "Columbia",
"state": "Missouri",
"country": "United States",
"status": "",
"lat": 38.95171,
"lon": -92.33407
}
] | {
"criteria": "Inclusion Criteria:\n\n* Definite ALS\n* Severe fatigue (defined by FSS \\> 4.0)\n* Expanded Disability Status Scale (EDSS) (measure of neurological impairment) 0 - 7.5 Able to comply with study procedures\n* Stable medication for the past month prior to enrollment.\n\nExclusion Criteria:\n\n* na",
"... | {
"compound": "PolyMVA",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT04436497 | HEALEY ALS Platform Trial - Regimen A Zilucoplan | PHASE2, PHASE3 | COMPLETED | INTERVENTIONAL | false | Merit E. Cudkowicz, MD | The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.
Regimen A will evaluate the safety and efficacy of a single study drug, zilucoplan, in participants with ALS. | [
{
"type": "DRUG",
"name": "Zilucoplan"
},
{
"type": "DRUG",
"name": "Matching Placebo"
}
] | 2020-07-29 | https://clinicaltrials.gov/study/NCT04436497 | [
"Complement component C5"
] | [
{
"facility": "Healey Center for ALS at Mass General",
"city": "Boston",
"state": "Massachusetts",
"country": "United States",
"status": "",
"lat": 42.35843,
"lon": -71.05977
}
] | {
"criteria": "Inclusion Criteria:\n\n* The following inclusion criterion is in addition to the inclusion criteria specified in the Master Protocol (NCT NCT04297683).\n\n 1. Vaccination with a quadrivalent meningococcal vaccine and meningococcal serotype B vaccine at least 14 days prior to the first dose of study dr... | {
"compound": "Zilucoplan",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT01823380 | Influence of the Vitamin D Blood Levels on the Amyotrophic Lateral Sclerosis Phenotype | NA | COMPLETED | INTERVENTIONAL | false | University Hospital, Montpellier | The main objective of this study is to investigate the correlation between the rate of motor decline and blood levels of Vitamin D total. Secondary objectives are to investigate the relationship between blood levels of vitamin D and total disease duration of ALS, forced vital capacity, weight loss, age of onset and the... | [
{
"type": "PROCEDURE",
"name": "Blood test"
}
] | 2012-09 | https://clinicaltrials.gov/study/NCT01823380 | [] | [
{
"facility": "UH Montpellier",
"city": "Montpellier",
"state": "",
"country": "France",
"status": "",
"lat": 43.61093,
"lon": 3.87635
}
] | {
"criteria": "Inclusion Criteria:\n\n* Subject with possible, probable or definite Amyotrophic Lateral Sclerosis (ALS).\n* ALS operating for less than three years at dosage of vitamin D time.\n* Subject monitored in the center ALS of Montpellier for 6 months.\n* Subject agreeing to give his consent in writing or ora... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT02795052 | Neurologic Stem Cell Treatment Study | NA | RECRUITING | INTERVENTIONAL | false | MD Stem Cells | This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1/3 of the nasal passages in order to determine if such a treatment will provide improvement in neurologic function for patients with certain neurologic conditions.... | [
{
"type": "PROCEDURE",
"name": "Intravenous and Intranasal BMSC"
}
] | 2016-06 | https://clinicaltrials.gov/study/NCT02795052 | [
"neural_regeneration_neuroprotection"
] | [
{
"facility": "MD Stem Cells",
"city": "Westport",
"state": "Connecticut",
"country": "United States",
"status": "RECRUITING",
"lat": 41.14149,
"lon": -73.3579
},
{
"facility": "MD Stem Cells",
"city": "Coral Springs",
"state": "Florida",
"country": "United States",
... | 203-423-9494 | stevenlevy@mdstemcells.com | {
"criteria": "Inclusion Criteria:\n\n1. Have documented functional damage to the central or peripheral nervous system unlikely to improve with present standard of care.\n2. Be at least 6 months post-onset of the disease.\n3. If under current medical therapy (pharmacologic or surgical treatment) for the condition be ... | {
"compound": "Autologous bone marrow derived stem cells (BMSC)",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "Bone marrow-derived stem cells demonstrate potential for motor neuron protection in SOD1G93A mouse models of ALS.",
"animal_results_pmid": "31189354",
"repur... |
NCT03900247 | Restore Motor Function Through Robotic Arm Exoskeleton and Brain Computer Interface | NA | UNKNOWN | INTERVENTIONAL | false | University of Aarhus | The current project will aid patients with motor impairment to reduce the need for homecare. Specifically the aim is to develop and implement a robotic exoskeleton and brain computer interface to assist and eventually perform arm and hand movement in patients with the progressive neurodegenerative disease ALS. This pro... | [
{
"type": "DEVICE",
"name": "REMAP EEG based BCI and SEM-Glove BioServo"
}
] | 2019-03-18 | https://clinicaltrials.gov/study/NCT03900247 | [] | [
{
"facility": "Center of Functionally Integrative Neuroscience",
"city": "Aarhus",
"state": "",
"country": "Denmark",
"status": "",
"lat": 56.15674,
"lon": 10.21076
}
] | {
"criteria": "Inclusion Criteria:\n\n* ALS according to the latest revision of El Escorial Criteria (Ludorph et al. 2015)\n* Loss of muscle force or fine motor skills in a hand\n\nExclusion Criteria:\n\n* Other severe Neurological or Psychiatric disease\n* Drug or Alcohol dependency\n* Pregnancy\n* Severe cognitive ... | {
"compound": "REMAP EEG based BCI and SEM-Glove BioServo",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT01639391 | Creation of a Bank of Fibroblast From Patients With Amyotrophic Lateral Sclerosis: Pilot Study | NA | COMPLETED | INTERVENTIONAL | false | Institut Pasteur | Patients with ALS will be included in the reference center for ALS in hospital La Pitié Salpêtrière, Paris.
The study proposes to investigate the pathophysiology of ALS by setting up a fibroblast bank for studying molecular, cellular and genetic parameters of the pathology.
iPS (induced pluripotent stem cells) and th... | [
{
"type": "PROCEDURE",
"name": "skin biopsy"
}
] | 2012-11-29 | https://clinicaltrials.gov/study/NCT01639391 | [] | [
{
"facility": "Centre référent maladies rares SLA",
"city": "Paris",
"state": "",
"country": "France",
"status": "",
"lat": 48.85341,
"lon": 2.3488
}
] | {
"criteria": "Inclusion Criteria:\n\n* patients over 18 years old\n* ALS sporadic or familial or unknown\n\nExclusion Criteria:\n\n* known cutaneous disease not allowing the biopsy\n* platelets less than 10 000/m3\n* suspected or known xylocain allergy",
"sex": "ALL",
"min_age": "18 Years",
"max_age": "",
"h... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT04257760 | Evaluation of Palliative Care for Patients With ALS and Their Caregivers | NA | COMPLETED | INTERVENTIONAL | false | Ottawa Hospital Research Institute | Rationale: Amyotrophic lateral sclerosis (ALS) is a degenerative illness which currently has no medical cure. It is routinely accompanied by a significant symptom burden including high levels of distress in patients and their caregivers. As a result, an early palliative care approach is recommended in the ALS populatio... | [
{
"type": "BEHAVIORAL",
"name": "Palliative Care consultation outside standard of care"
}
] | 2020-10-08 | https://clinicaltrials.gov/study/NCT04257760 | [] | [
{
"facility": "The Ottawa Hospital",
"city": "Ottawa",
"state": "Ontario",
"country": "Canada",
"status": "",
"lat": 45.41117,
"lon": -75.69812
}
] | {
"criteria": "Inclusion Criteria:\n\nPatient with ALS at the Ottawa Hospital ALS clinic or caregiver of participating patient.\n\nExclusion Criteria:\n\nSignificant cognitive impairment Prior palliative care consultation",
"sex": "ALL",
"min_age": "",
"max_age": "",
"healthy_volunteers": false,
"std_ages":... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT06249412 | The Importance of Positive Expiratory Pressure Associated With the In-exsufflator in ALS Patients | NA | RECRUITING | INTERVENTIONAL | false | Groupe Hospitalier du Havre | Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disorder that impairs motor neurons, with a life expectancy of 2 to 7 years after diagnosis. ALS manifests as 'spinal' when it primarily affects limbs, or 'bulbar' when it impairs speech and swallowing. The disease progressively weakens all skeletal muscl... | [
{
"type": "DEVICE",
"name": "MI-E with PEP function activated during the pause"
},
{
"type": "DEVICE",
"name": "MI-E without PEP function activated during the pause"
}
] | 2024-12-19 | https://clinicaltrials.gov/study/NCT06249412 | [] | [
{
"facility": "GH Havre",
"city": "Le Havre",
"state": "Normandy",
"country": "France",
"status": "RECRUITING",
"lat": 49.49346,
"lon": 0.10785
}
] | +332 32 73 32 32 | yann.combret@ch-havre.fr | {
"criteria": "Inclusion Criteria:\n\n* Male or female patient aged over 18 years\n* Patient with Amyotrophic Lateral Sclerosis (ALS)\n* Patients with established or beginning bulbar disorders, identified by the healthcare team (speech impairment, hypersalivation, or swallowing difficulties)\n* Patient naive to INEX ... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT04309604 | IC14 for ALS Patients Expanded Access | Expanded Access | NO_LONGER_AVAILABLE | EXPANDED_ACCESS | true | Implicit Bioscience | The primary objective is to provide the investigational product, IC14, at the dose of 8 mg/kg intravenously every 2 weeks for 12 weeks to 6 participants with amyotrophic lateral sclerosis (ALS). No clinical hypotheses are being tested. An extension for 6 additional doses every 2 weeks will be allowed if the drug is saf... | [
{
"type": "BIOLOGICAL",
"name": "IC14"
}
] | https://clinicaltrials.gov/study/NCT04309604 | [
"C5 complement component"
] | [
{
"facility": "Massachusetts General Hospital",
"city": "Boston",
"state": "Massachusetts",
"country": "United States",
"status": "",
"lat": 42.35843,
"lon": -71.05977
}
] | {
"criteria": "Inclusion Criteria:\n\n1. Signed informed consent prior to initiation of any program-specific procedures.\n2. Familial or sporadic ALS defined as clinically possible, probable, or definite by Awaji-Shima Consensus Recommendations or other standard guidance.\n3. Adequate hematologic, renal, and liver fu... | {
"compound": "IC14",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | |||
NCT07369076 | A Clinical Trial to Evaluate NB-4746 in Participants With Amyotrophic Lateral Sclerosis. | PHASE1, PHASE2 | RECRUITING | INTERVENTIONAL | false | Nura Bio | The purpose of this trial is to learn about the effects of NB-4746 compared with placebo in people with amyotrophic lateral sclerosis.
The questions this trial aims to answer in comparing NB-4746 to placebo are:
* What adverse events associated with taking NB-4746 are reported during this trial? (An adverse event is ... | [
{
"type": "DRUG",
"name": "NB-4746 High dose"
},
{
"type": "DRUG",
"name": "NB-4746 Low dose"
},
{
"type": "DRUG",
"name": "Placebo"
},
{
"type": "DRUG",
"name": "NB-4746 (Dose TBD)"
}
] | 2026-03-04 | https://clinicaltrials.gov/study/NCT07369076 | [
"astrocyte_activation_neuroinflammation"
] | [
{
"facility": "Concord Repatriation General Hospital",
"city": "Concord",
"state": "New South Wales",
"country": "Australia",
"status": "RECRUITING",
"lat": -33.84722,
"lon": 151.10381
},
{
"facility": "Neuroscience Research Australia",
"city": "Randwick",
"state": "New S... | 801-918-7637 | lmehta@nurabio.com | {
"criteria": "Inclusion Criteria:\n\n\\- ALS Criteria for Phase 1b:\n\n1. Participants in Phase 1b must have:\n\n 1. Diagnosis of ALS per Gold Coast Criteria; and\n 2. Symptom onset ≤48 months prior to randomization on Day 1. Date of first ALS symptom (any ALS symptom) onset is defined as the onset of weakness i... | {
"compound": "NB-4746",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT04800926 | Xavier Electromyographic Wheelchair Control for Limited Mobility Patients | NA | COMPLETED | INTERVENTIONAL | false | Mayo Clinic | The purpose of this study is to assess the functional mobility and self-reported satisfaction with the Xavier electromyography hands-free wheelchair control system in comparison with a standard joystick. | [
{
"type": "DEVICE",
"name": "Xavier wheelchair controller"
}
] | 2019-01-11 | https://clinicaltrials.gov/study/NCT04800926 | [] | [
{
"facility": "Mayo Clinic in Florida",
"city": "Jacksonville",
"state": "Florida",
"country": "United States",
"status": "",
"lat": 30.33218,
"lon": -81.65565
}
] | {
"criteria": "Inclusion Criteria:\n\n* ALS diagnosis by revised el Escorial criteria (definite, probable or probable laboratory supported)\n* Age 18-89\n* Limited mobility with use of motorized wheelchair at screening-time\n* Impairment of hand function limiting the use of a standard joystick control\n* Caregiver wi... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT01709149 | Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | COMPLETED | INTERVENTIONAL | false | Cytokinetics | The purpose of this research study is to evaluate the safety and effectiveness of CK-2017357 when taken with or without riluzole (also called Rilutek®) in patients with Amyotrophic Lateral Sclerosis (ALS). | [
{
"type": "DRUG",
"name": "CK-2017357"
},
{
"type": "OTHER",
"name": "Placebo tablets"
},
{
"type": "DRUG",
"name": "Riluzole"
}
] | 2012-10 | https://clinicaltrials.gov/study/NCT01709149 | [
"Skeletal muscle fiber"
] | [
{
"facility": "Barrow Neurology",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "University of California, San Diego",
"city": "La Jolla",
"state": "California",
"country": "United ... | {
"criteria": "Inclusion Criteria:\n\n1. Able to comprehend and willing to sign an Informed Consent Form (ICF)\n2. Male or female 18 years of age or older\n3. A diagnosis of familial or sporadic ALS (defined as meeting the possible, laboratory-supported probable, probable, or definite criteria for a diagnosis of ALS ... | {
"compound": "CK-2017357",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT06111014 | Continuation Study for Latozinemab | PHASE3 | TERMINATED | INTERVENTIONAL | false | Alector Inc. | Continuation study to provide continued access to latozinemab for participants who have previously participated in a latozinemab study | [
{
"type": "DRUG",
"name": "Latozinemab"
}
] | 2023-12-08 | https://clinicaltrials.gov/study/NCT06111014 | [
"Amyloid beta"
] | [
{
"facility": "Dignity Health - Arizona",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "Mayo Comprehensive Cancer Center - PPDS",
"city": "Rochester",
"state": "Minnesota",
"countr... | {
"criteria": "Inclusion Criteria:\n\n* Written informed consent must be obtained and documented (from the participant or, where jurisdictions allow it, from their legal decision maker).\n* Has successfully completed participation in their parent latozinemab study.\n* Female participants must be nonpregnant and nonla... | {
"compound": "Latozinemab",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT00537446 | Effect of Noninvasive Ventilation on Lung Function in Amyotrophic Lateral Sclerosis | NA | TERMINATED | INTERVENTIONAL | false | Columbia University | Amyotrophic Lateral Sclerosis (ALS), or "Lou Gehrig's Disease", is a fatal disorder that causes progressive degeneration and weakening of the muscles of breathing, leading to breathing insufficiency and eventually breathing failure. This breathing insufficiency is commonly treated with a breathing assistance device, kn... | [
{
"type": "DEVICE",
"name": "noninvasive positive pressure ventilation"
},
{
"type": "DEVICE",
"name": "noninvasive positive pressure ventilation"
}
] | 2007-09 | https://clinicaltrials.gov/study/NCT00537446 | [] | [
{
"facility": "Eleanor and Lou Gehrig ALS/MDA Center at Columbia University",
"city": "New York",
"state": "New York",
"country": "United States",
"status": "",
"lat": 40.71427,
"lon": -74.00597
}
] | {
"criteria": "Inclusion Criteria:\n\n* clinical diagnosis of amyotrophic lateral sclerosis\n* clinical indication to start noninvasive ventilation (forced vital capacity \\< 50% predicted or signs/symptoms of respiratory insufficiency)\n* age 18 to 80 years old\n\nExclusion Criteria:\n\n* prior institution of NIPPV\... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT05395624 | Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers | PHASE1, PHASE2 | RECRUITING | INTERVENTIONAL | false | Ashvattha Therapeutics, Inc. | This is a Phase 1/2 study to evaluate the safety and tolerability of 18F-OP-801 in subjects with ALS, AD, MS, PD and age-matched HVs. 18F-OP-801 is intended as a biomarker for PET imaging of activated microglia and macrophages in regions of neuroinflammation. | [
{
"type": "DRUG",
"name": "18F-OP-801"
}
] | 2023-02-02 | https://clinicaltrials.gov/study/NCT05395624 | [
"neuroinflammation"
] | [
{
"facility": "UCSF",
"city": "San Francisco",
"state": "California",
"country": "United States",
"status": "RECRUITING",
"lat": 37.77493,
"lon": -122.41942
},
{
"facility": "Stanford University",
"city": "Stanford",
"state": "California",
"country": "United States",
... | 408-476-4172 | jcheung@avttx.com | {
"criteria": "Inclusion Criteria:\n\n1. Has the ability to understand and sign the written ICF and local medical privacy authorization forms, which must be obtained prior to the conduct of any study related procedures.\n2. Female subjects of non-childbearing potential must be either surgically sterile (hysterectomy,... | {
"compound": "18F-OP-801",
"targeting_mechanism": "Biomarker for PET imaging of activated microglia and macrophages in regions of neuroinflammation",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT02460679 | Safety and Biomarker Study of EPI-589 in Participants With Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | COMPLETED | INTERVENTIONAL | false | PTC Therapeutics | This is an open label study with 30-day run in phase to establish baseline parameters, 90-day treatment phase, and a 90-day withdrawal phase to determine long-term effects, duration of treatment response, and potential effects of EPI-589 therapy on known trajectory. | [
{
"type": "DRUG",
"name": "EPI-589"
}
] | 2016-01-14 | https://clinicaltrials.gov/study/NCT02460679 | [
"TARDBP"
] | [
{
"facility": "Cedar's Sinai",
"city": "Los Angeles",
"state": "California",
"country": "United States",
"status": "",
"lat": 34.05223,
"lon": -118.24368
},
{
"facility": "California Pacific Medical Center",
"city": "San Francisco",
"state": "California",
"country": "... | {
"criteria": "Inclusion Criteria:\n\n* Diagnosis of possible, probable, laboratory supported probable, or definite ALS by E1 Escorial Criteria\n* Forced vital capacity (FVC) ≥ 70% of predicted\n* Weakness onset within 3 years\n* Agreement to use contraception if within reproductive years\n* Willingness and ability t... | {
"compound": "EPI-589",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT03945279 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral Sclerosis | PHASE1 | COMPLETED | INTERVENTIONAL | false | Biogen | The primary objective of this study is to evaluate the safety, tolerability of single-ascending doses of BIIB100 in adults with amyotrophic lateral sclerosis (ALS). The secondary objective of the study is to characterize the pharmacokinetic profile of BIIB100. | [
{
"type": "DRUG",
"name": "BIIB100"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2019-05-30 | https://clinicaltrials.gov/study/NCT03945279 | [
"TBK1"
] | [
{
"facility": "Barrow Neurological Institute",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "University of California San Diego Medical Center",
"city": "San Diego",
"state": "Californ... | {
"criteria": "Key Inclusion Criteria:\n\n* Must meet the laboratory-supported probable, probable, or definite criteria for diagnosing ALS according to the World Federation of Neurology El Escorial criteria.\n* Participants taking concomitant riluzole at study entry must be on a stable dose for greater than or equals... | {
"compound": "BIIB100",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT04944784 | A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS) | PHASE3 | TERMINATED | INTERVENTIONAL | false | Cytokinetics | The purpose of this study is to assess the effect of reldesemtiv versus placebo on functional outcomes in ALS. | [
{
"type": "DRUG",
"name": "Reldesemtiv"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2021-08-16 | https://clinicaltrials.gov/study/NCT04944784 | [
"neuromuscular_junction_function"
] | [
{
"facility": "St. Joseph's Hospital & Medical Center - Barrow Neurological Institute",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "Cedars-Sinai Medical Center",
"city": "Los Angeles",
... | {
"criteria": "Key Inclusion Criteria:\n\n* Males or Females between the ages of 18 and 80 years of age, inclusive\n* Diagnosis of familial or sporadic ALS (defined as meeting the laboratory-supported probable, probable, or definite criteria for ALS according to the World Federation of Neurology El Escorial criteria)... | {
"compound": "Reldesemtiv",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT03651349 | To Determine the Maximum Tolerated Dose (MTD) of HK-001 in Healthy Volunteers | PHASE1 | ACTIVE_NOT_RECRUITING | INTERVENTIONAL | false | Everfront Biotech Co., Ltd. | Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts. After single dose administration, followed by an independent Data and Safety Monitoring Board (DSMB) meeting for safety assessments (including the available plasma pharmacokinetic profile), the subjec... | [
{
"type": "DRUG",
"name": "HK-001"
},
{
"type": "DRUG",
"name": "Placebo control"
}
] | 2021-02-01 | https://clinicaltrials.gov/study/NCT03651349 | [] | [
{
"facility": "Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation",
"city": "Hualien City",
"state": "",
"country": "Taiwan",
"status": "",
"lat": 23.97694,
"lon": 121.60444
}
] | {
"criteria": "Inclusion Criteria:\n\n1. Subject's age is no less than 20 years old.\n2. Subjects whose body mass index (BMI) at screening is within a range of ≥18.5 kg/m2 and \\<25.0 kg/m2.\n\n BMI = Body Weight (kg) / \\[Height (m)\\]2 And body weight is not less than 50 kg and 45 kg for males and females, respec... | {
"compound": "HK-001",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT05105958 | Tideglusib for the Treatment of Amyotrophic Lateral Sclerosis | PHASE2 | NOT_YET_RECRUITING | INTERVENTIONAL | false | University of Zurich | Amyotrophic lateral sclerosis (ALS) is a severe neurodegenerative condition, mainly characterized by progressive weakness and wasting of the limbs, the respiratory and bulbar muscles. Respiratory insufficiency leads to a fatal outcome after a mean diseases duration of only three to five years. The disease is characteri... | [
{
"type": "DRUG",
"name": "Tideglusib"
}
] | 2025-12-01 | https://clinicaltrials.gov/study/NCT05105958 | [
"TARDBP",
"GSK3"
] | [
{
"facility": "University Hospital Bern",
"city": "Bern",
"state": "",
"country": "Switzerland",
"status": "",
"lat": 46.94809,
"lon": 7.44744
},
{
"facility": "University Hospital Geneva",
"city": "Geneva",
"state": "",
"country": "Switzerland",
"status": "",
... | 0795531171 | annemarie.hubers@hcuge.ch | {
"criteria": "Inclusion Criteria:\n\n* Possible, probable (clinically or laboratory supported) or definite ALS according to the revised version of the El Escorial criteria\n* Disease duration \\< 18 months\n* Vital capacity of more than 60% of normal (defined as slow vital capacity, best of three measurements)\n* Ag... | {
"compound": "Tideglusib",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT04651855 | The Evaluation of the Effect of Mesenchymal Stem Cells on the Immune System of Patients With ALS | PHASE1, PHASE2 | UNKNOWN | INTERVENTIONAL | false | Polski Bank Komorek Macierzystych JSC (PBKM) | The objective of this study is to evaluate the safety of intrathecal administration of Wharton's Jelly Mesenchymal Stem Cells (WJMSC) and the impact on the immune system of patients with Amyotrophic Lateral Sclerosis. | [
{
"type": "DRUG",
"name": "Mesenchymal stem cells isolated from Wharton's jelly"
}
] | 2020-12-02 | https://clinicaltrials.gov/study/NCT04651855 | [
"neuroinflammation"
] | [
{
"facility": "JST sp. z o.o.",
"city": "Częstochowa",
"state": "",
"country": "Poland",
"status": "",
"lat": 50.79646,
"lon": 19.12409
}
] | {
"criteria": "Inclusion Criteria:\n\n1. Adult patients (at least 18 years old)\n2. The minimum patient's weight is not less than 40 kg\n3. Diagnosis of sporadic ALS, definite or probable, as defined by El Escorial World Federation of Neurology criteria\n4. History of ALS symptoms less than 2 years duration from the ... | {
"compound": "Mesenchymal stem cells isolated from Wharton's jelly",
"targeting_mechanism": "Intrathecal-delivered stem cells differentiate into support cells and produce growth factors and anti-inflammatory cytokines to modulate neuroinflammation and benefit degenerating motor neurons.",
"targeting_mechanism_pm... | ||
NCT07221240 | Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Amisodin in Healthy Adult Subjects With Amyotrophic Lateral Sclerosis | PHASE1 | RECRUITING | INTERVENTIONAL | false | PRG Science & Technology Co., Ltd. | Researchers will evaluate the safety, tolerability, and pharmacokinetics (PK) of orally administered Amisodin in healthy adult subjects through a randomized, double-blind, placebo-controlled Phase 1 study consisting of two parts: single ascending dose (SAD) and multiple ascending dose (MAD). The food effect will be ass... | [
{
"type": "DRUG",
"name": "Amisodin"
},
{
"type": "OTHER",
"name": "Placebo"
}
] | 2025-10-01 | https://clinicaltrials.gov/study/NCT07221240 | [
"NEK1"
] | [
{
"facility": "Pharmaron, Inc.",
"city": "Baltimore",
"state": "Maryland",
"country": "United States",
"status": "RECRUITING",
"lat": 39.29038,
"lon": -76.61219
}
] | +82 051-583-8703 | claudiajang@kcrnresearch.com | {
"criteria": "Inclusion Criteria:\n\nSubjects must fulfill all of the following inclusion criteria to be eligible for participation in the study:\n\n* 1\\. Healthy, adult, male or female (of non-childbearing potential only)\\*, 18 55 years of age, inclusive, at the screening visit.\n\n * Females of non-childbearing... | {
"compound": "Amisodin",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT05136222 | Polysomnographic Titration of Non-invasive Ventilation in Motor Neurone Disease | NA | RECRUITING | INTERVENTIONAL | false | University of Melbourne | A two-arm, individual participant randomised controlled, assessor-blinded trial in 7 MND care centres across Australia will be undertaken. | [
{
"type": "OTHER",
"name": "Intervention polysomnography"
},
{
"type": "OTHER",
"name": "Sham polysomnography"
}
] | 2021-12-15 | https://clinicaltrials.gov/study/NCT05136222 | [
"respiratory_function"
] | [
{
"facility": "Flinders Medical Centre",
"city": "Adelaide",
"state": "",
"country": "Australia",
"status": "NOT_YET_RECRUITING",
"lat": -34.92866,
"lon": 138.59863
},
{
"facility": "The Prince Charles Hospital",
"city": "Brisbane",
"state": "",
"country": "Australia"... | +613 9496 3871 | david.berlowitz@austin.org.au | {
"criteria": "Inclusion Criteria:\n\n* Age \\>18 years\n* Clinical indication to commence long term NIV\n* Confirmed clinical diagnosis of underlying condition\n\nExclusion Criteria:\n\n* Medically unstable\n* Hypoventilation attributable to medications with sedative/respiratory depressant side- effects\n* Use of NI... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT03326622 | Exercise and Disease Progression in Amyotrophic Lateral Sclerosis Patients | NA | COMPLETED | INTERVENTIONAL | false | University of Lisbon | This study evaluated the influence of a tailored aerobic exercise protocol on the functional outcome in ALS patients. In addition, the investigators compare some CPET variables collected during exercise testing in both groups. | [
{
"type": "OTHER",
"name": "standard care"
},
{
"type": "OTHER",
"name": "moderate exercise"
}
] | 2013-07-01 | https://clinicaltrials.gov/study/NCT03326622 | [
"mitochondrial_function"
] | [] | {
"criteria": "Inclusion Criteria:\n\n* Consecutive patients diagnosed with definite, probable, or probable laboratory supported ALS\n* Disease duration from first symptoms between 6-24 months to exclude slow and fast progression\n* ALSFRS-R ≥ 30\n* FVC (%predicted) ≥ 70%\n\nExclusion Criteria:\n\n* Other medical con... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT01609283 | A Dose-escalation Safety Trial for Intrathecal Autologous Mesenchymal Stem Cell Therapy in Amyotrophic Lateral Sclerosis | PHASE1 | COMPLETED | INTERVENTIONAL | false | Mayo Clinic | The purpose of this study is to determine determine the safety of intraspinal delivery of mesenchymal stem cells (MSCs) to the cerebral spinal fluid of patients with Amyotrophic Lateral Sclerosis (ALS) using a dose-escalation study. | [
{
"type": "BIOLOGICAL",
"name": "autologous mesenchymal stem cells"
}
] | 2012-05 | https://clinicaltrials.gov/study/NCT01609283 | [
"neuroinflammation"
] | [
{
"facility": "Mayo Clinic",
"city": "Rochester",
"state": "Minnesota",
"country": "United States",
"status": "",
"lat": 44.02163,
"lon": -92.4699
}
] | {
"criteria": "Inclusion Criteria:\n\n* All patients must have clinically-defined ALS as defined by the World Federation of Neurology criteria\n* Age greater than 18 years\n* If female, must be post-menopausal or had a hysterectomy\n* Permanent resident or citizen of the United States\n* History of a chronic onset of... | {
"compound": "autologous mesenchymal stem cells",
"targeting_mechanism": "Intraspinal-delivered mesenchymal stem cells differentiate into support cells (astrocytes, oligodendrocytes, microglia) and produce growth factors and anti-inflammatory cytokines to protect degenerating motor neurons.",
"targeting_mechanis... | ||
NCT04868994 | Magnetic Imaging for Diagnostic of Amyotrophic Lateral Sclerosis | NA | UNKNOWN | INTERVENTIONAL | false | University Hospital, Toulouse | Nearly 60% of Amyotrophic Lateral Sclerosis (ALS) patients have a low level of diagnostic certainty (possible, probable) at the time of diagnosis. In the absence of biomarkers, this diagnosis is based, among other things, on the demonstration of the diffusion of signs of denervation by electroneuromyography (ENMG). The... | [
{
"type": "DIAGNOSTIC_TEST",
"name": "Whole Body MRI and ENMG"
}
] | 2021-06-01 | https://clinicaltrials.gov/study/NCT04868994 | [] | [
{
"facility": "Pascal CINTAS",
"city": "Toulouse",
"state": "",
"country": "France",
"status": "RECRUITING",
"lat": 43.60426,
"lon": 1.44367
}
] | 05 61 77 94 40 | cintas.p@chu-toulouse.fr | {
"criteria": "Inclusion Criteria:\n\n* Consent form signed by the patient\n* Patients suspected ALS defined according Awaji Shima criteria (possible, probable, defined)\n* Clinical assessment of upper motor neuron involvement\n* Electrophysiologic assessment of lower motor neuron involvement\n\nExclusion Criteria:\n... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT03757351 | Study to Evaluate DNL747 in Subjects With Amyotrophic Lateral Sclerosis | PHASE1 | TERMINATED | INTERVENTIONAL | false | Sanofi | The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple oral doses of DNL747 in subjects with Amyotrophic Lateral Sclerosis in a cross-over design | [
{
"type": "DRUG",
"name": "DNL747"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2018-12-14 | https://clinicaltrials.gov/study/NCT03757351 | [
"dnl747"
] | [
{
"facility": "Bioclinica",
"city": "Orlando",
"state": "Florida",
"country": "United States",
"status": "",
"lat": 28.53834,
"lon": -81.37924
},
{
"facility": "PRA Health Sciences",
"city": "Salt Lake City",
"state": "Utah",
"country": "United States",
"status": ... | {
"criteria": "Key Inclusion Criteria (Double-Blind Part):\n\n* Women of non-childbearing potential and men, aged 21-80 years\n* Willingness and ability to complete all aspects of the study; participant should be capable of completing assessments either alone or with help of a caregiver\n* Diagnosis of laboratory-sup... | {
"compound": "DNL747",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT01119001 | A P300 Brain Computer Interface Keyboard to Control Assistive Technology For Use by People With Amyotrophic Lateral Sclerosis | NA | COMPLETED | INTERVENTIONAL | false | University of Michigan | People with Amyotrophic Lateral Sclerosis (ALS) will use a P300 based brain computer interface (BCI) keyboard to type in assistive technology devices. The results of this study will be compared with a previous study of a P300 BCI keyboard used by healthy volunteers. | [
{
"type": "DEVICE",
"name": "P300 Brain Computer Interface Keyboard"
}
] | 2010-02 | https://clinicaltrials.gov/study/NCT01119001 | [] | [
{
"facility": "University of Michigan",
"city": "Ann Arbor",
"state": "Michigan",
"country": "United States",
"status": "",
"lat": 42.27756,
"lon": -83.74088
}
] | {
"criteria": "Inclusion Criteria:\n\n* Age 18 or older.\n* Diagnosed with cerebral palsy, spinal cord injury, neuromuscular disease, or ALS that results in impaired hand and arm function making it difficult to manipulate objects (if at all) and requires help to prepare or modify activities\n* Able to see the BCI dis... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT04468919 | Optimizing BCI-FIT: Brain Computer Interface - Functional Implementation Toolkit | NA | COMPLETED | INTERVENTIONAL | false | Oregon Health and Science University | This project adds to non-invasive BCIs for communication for adults with severe speech and physical impairments due to neurodegenerative diseases. Researchers will optimize \& adapt BCI signal acquisition, signal processing, natural language processing, \& clinical implementation. BCI-FIT relies on active inference and... | [
{
"type": "BEHAVIORAL",
"name": "BCI-FIT multi-modal access"
},
{
"type": "BEHAVIORAL",
"name": "BCI-FIT adaptive signal modeling"
},
{
"type": "BEHAVIORAL",
"name": "BCI-FIT active querying"
},
{
"type": "BEHAVIORAL",
"name": "BCI-FIT language modeling"
}
] | 2022-07-15 | https://clinicaltrials.gov/study/NCT04468919 | [] | [
{
"facility": "Oregon Health & Science University",
"city": "Portland",
"state": "Oregon",
"country": "United States",
"status": "",
"lat": 45.52345,
"lon": -122.67621
}
] | {
"criteria": "Inclusion Criteria:\n\nControls\n\n* Able to read and communicate in English\n* Capable of participating in study visits lasting 1-3 hours\n* Adequate visuospatial skills to select letters, words, or icons to copy or generate messages\n* Live within a 2-hour drive of OHSU or is willing to travel to OHS... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT07396818 | Kamlanoflast In Amyotrophic Lateral Sclerosis | PHASE1, PHASE2 | NOT_YET_RECRUITING | INTERVENTIONAL | false | Inflammasome Therapeutics | This is a study of Kamlanoflast in patients with ALS. Kamlanoflast is orally administered over 24 weeks. Its effects on inflammatory and functional parameters will be studied. Information on safety and tolerability will be collected. | [
{
"type": "DRUG",
"name": "Kamlanoflast"
},
{
"type": "DRUG",
"name": "Kamlanoflast"
}
] | 2026-02 | https://clinicaltrials.gov/study/NCT07396818 | [
"kamlanoflast"
] | [] | {
"criteria": "Inclusion Criteria:\n\n1. Diagnosis of definite, probable, laboratory-supported probable, or possible ALS by revised El Escorial research criteria.\n2. Ages 18 to 75 years.\n3. Onset of weakness within three years of study enrollment.\n4. ALS with progression, characterized either by:\n\ni. a reduction... | {
"compound": "Kamlanoflast",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT01384162 | An Open Label, Safety and Tolerability Continuation Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral Sclerosis | PHASE1, PHASE2 | TERMINATED | INTERVENTIONAL | false | Newron Sweden AB | This is an open label safety and tolerability continuation study of intracerebroventricular administration of sNN0029, containing the growth factor VEGF165, in patients with amyotrophic lateral sclerosis that have previously participated in study sNN0029-001. The intention of the study is to investigate safety and tole... | [
{
"type": "DRUG",
"name": "sNN0029"
}
] | 2009-06 | https://clinicaltrials.gov/study/NCT01384162 | [
"VEGF"
] | [
{
"facility": "University Hospital Leuven, Department of Neurology",
"city": "Leuven",
"state": "",
"country": "Belgium",
"status": "",
"lat": 50.87959,
"lon": 4.70093
}
] | {
"criteria": "Inclusion Criteria:\n\n1. Clinical diagnosis of ALS classified as definite, or probable with or without additional laboratory evidence, according to the revised WFN El Escorial criteria (Appendix B).\n2. Previous participation in study sNN0029-001 with completion of 12 weeks study drug administration.\... | {
"compound": "sNN0029",
"targeting_mechanism": "Intracerebroventricular delivery of VEGF165 growth factor to promote motor neuron survival and function.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": "... | ||
NCT03944447 | Outcomes Mandate National Integration With Cannabis as Medicine | PHASE2 | UNKNOWN | INTERVENTIONAL | false | OMNI Medical Services, LLC | This will be a multistate, multicenter clinical study to determine the efficacy and safety of medical cannabis for a wide variety of chronic medical conditions. | [
{
"type": "DRUG",
"name": "Cannabis, Medical"
},
{
"type": "DEVICE",
"name": "RYAH-Medtech Inhaler"
}
] | 2018-12-01 | https://clinicaltrials.gov/study/NCT03944447 | [] | [
{
"facility": "OMNI Medical Services",
"city": "Boca Raton",
"state": "Florida",
"country": "United States",
"status": "RECRUITING",
"lat": 26.35869,
"lon": -80.0831
},
{
"facility": "OMNI Medical Services",
"city": "Bradenton",
"state": "Florida",
"country": "United ... | 419-214-3220 | ryan.lakin.md@gmail.com | {
"criteria": "Inclusion Criteria:\n\n* Clinical diagnosis of a Qualifying Condition for Medical Marijuana\n* Must be 18 years or older unless they have consent from their parent or legal guardian as defined under state law parameters\n* Must be willing to complete online surveys at baseline and the follow up points ... | {
"compound": "Medical Cannabis (THC:CBD)",
"targeting_mechanism": "Targeting CB2 receptors on astrocytes and other endocannabinoid system elements to exert anti-excitotoxicity, anti-oxidant and anti-inflammatory effects in ALS.",
"targeting_mechanism_pmid": "33486755",
"animal_results": "In SOD1(G93A) transgen... |
NCT03114215 | Effect of MD1003 in Amyotrophic Lateral Sclerosis | PHASE2 | COMPLETED | INTERVENTIONAL | false | MedDay Pharmaceuticals SA | This is a 6-month double blind randomized 2:1 placebo-controlled study with two arms (placebo, biotin 300 mg/day). The study will be followed by a 6-month extension phase during which all patients will receive biotin 300 mg/day. | [
{
"type": "DRUG",
"name": "MD1003"
},
{
"type": "DRUG",
"name": "Placebo oral capsule"
}
] | 2016-06-29 | https://clinicaltrials.gov/study/NCT03114215 | [
"biotin"
] | [
{
"facility": "Hopital Gui De Chauliac",
"city": "Montpellier",
"state": "",
"country": "France",
"status": "",
"lat": 43.61093,
"lon": 3.87635
}
] | {
"criteria": "Inclusion Criteria:\n\n* Age: 25 to 80 years, inclusive\n* Male or female subjects with probable or confirmed ALS (revised international El Escorial criteria, Forbes et al., 2001).\n* Patients presenting first motor deficits due to ALS for a maximum of three years at the first consultation in an ALS ce... | {
"compound": "MD1003",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT00696332 | Talampanel for Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | COMPLETED | INTERVENTIONAL | false | Teva Branded Pharmaceutical Products R&D, Inc. | The purpose of this study is to assess the efficacy, tolerability and safety of oral administration of talampanel compared to a placebo in subjects with ALS. | [
{
"type": "DRUG",
"name": "Talampanel"
},
{
"type": "DRUG",
"name": "Talampanel"
},
{
"type": "OTHER",
"name": "placebo"
}
] | 2008-09 | https://clinicaltrials.gov/study/NCT00696332 | [
"glutamate_excitotoxicity"
] | [
{
"facility": "CA Medical Center for Movement Disorders-Forbes Norris MDA/ALS Research Center",
"city": "San Francisco",
"state": "California",
"country": "United States",
"status": "",
"lat": 37.77493,
"lon": -122.41942
},
{
"facility": "University of Kansas Medical Center - Dep... | {
"criteria": "Subjects with sporadic or familial ALS classified as definite, probable, or laboratory-supported probable ALS according to the revised El Escorial criteria.\n\nInclusion Criteria:\n\n1. Diagnosis of definite or probable ALS in accordance with the El-Escorial criteria.\n2. Subject has experienced his/he... | {
"compound": "Talampanel",
"targeting_mechanism": "AMPA receptor antagonist that blocks glutamatergic excitotoxicity to protect motor neurons from glutamate-mediated cell death.",
"targeting_mechanism_pmid": "27350567",
"animal_results": "The AMPA receptor antagonist perampanel robustly rescued ALS pathology i... | ||
NCT07414212 | Evaluation of the Combined Therapy of EH-301 and N-acetylcysteine Together With Riluzole in Amyotrophic Lateral Sclerosis (ALS) | PHASE1, PHASE2 | RECRUITING | INTERVENTIONAL | false | Biogipuzkoa Health Research Institute | This study is designed to evaluate whether a combination of N-acetylcysteine (NAC) and EH-301 can slow down or improve symptoms of amyotrophic lateral sclerosis (ALS). Researchers will assess changes in disease progression using the ALS Functional Rating Scale-Revised (ALSFRS-R), a standard tool for measuring daily fun... | [
{
"type": "DRUG",
"name": "Acetylcysteine"
},
{
"type": "DIETARY_SUPPLEMENT",
"name": "EH301"
},
{
"type": "DRUG",
"name": "Riluzole"
}
] | 2025-11-25 | https://clinicaltrials.gov/study/NCT07414212 | [
"oxidative_stress",
"riluzole"
] | [
{
"facility": "Hospital Universitario Donostia",
"city": "San Sebastián",
"state": "Guipuzcoa",
"country": "Spain",
"status": "RECRUITING",
"lat": 43.56667,
"lon": -5.9
}
] | +34 943006140 | lara.alamedacalvo@bio-gipuzkoa.eus | {
"criteria": "Inclusion Criteria:\n\n1. Patients diagnosed with ALS according to the Gold Coast criteria;\n2. Disease duration ≤ 18 months;\n3. Men and women aged 18 to 75 years;\n4. Total ALSFRS-R score ≥ 30 for all 12 categories;\n5. Forced vital capacity (FVC) ≥70%;\n6. The participant must receive treatment with... | {
"compound": "EH-301 and N-acetylcysteine (NAC) combined with Riluzole",
"targeting_mechanism": "N-acetylcysteine acts as an antioxidant to counteract oxidative stress, while riluzole blocks glutamatergic neurotransmission to reduce excitotoxicity; combined approach targets both oxidative stress and excitatory tox... |
NCT03489200 | EH301 for the Treatment of ALS | NA | COMPLETED | INTERVENTIONAL | false | Elysium Health | The objective of this trial is to evaluate the efficacy and tolerability of EH301 in patients with amyotrophic lateral sclerosis. Patients with ALS are randomized to receive either EH301 or placebo daily and undergo active evaluation for 6 months. | [
{
"type": "OTHER",
"name": "EH301"
},
{
"type": "OTHER",
"name": "Placebo"
}
] | 2017-01 | https://clinicaltrials.gov/study/NCT03489200 | [
"eh301"
] | [
{
"facility": "Universidad Católica de Valencia San Vicente Màrtir",
"city": "Valencia",
"state": "",
"country": "Spain",
"status": "",
"lat": 39.47391,
"lon": -0.37966
}
] | {
"criteria": "Inclusion Criteria:\n\n* 18 years or older\n* Diagnosis of probable or definite (sporadic or familial) ALS by El Escorial criteria\n* Onset of symptomatology for more than 6 months\n* If female: not lactating; negative pregnancy test; agree to use an effective method of birth control throughout study\n... | {
"compound": "EH301",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT00748501 | Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | COMPLETED | INTERVENTIONAL | false | Sangamo Therapeutics | The purpose of the study is to evaluate the effects of the investigational drug, SB-509 on progression of the disease in subjects with ALS | [
{
"type": "DRUG",
"name": "SB-509"
}
] | 2008-09 | https://clinicaltrials.gov/study/NCT00748501 | [
"GDNF"
] | [
{
"facility": "Coordinated Clinical Research",
"city": "La Jolla",
"state": "California",
"country": "United States",
"status": "",
"lat": 32.84727,
"lon": -117.2742
},
{
"facility": "University of California, Irvine; MDA ALS and Neuromuscular Center,",
"city": "Orange",
... | {
"criteria": "Inclusion Criteria:\n\n* Male or female between the ages of 18 and 85 with clinical diagnosis of ALS\n* Forced Vital Capacity (FVC) \\> 60% of predicted\n* Less than 3 years of ALS since the onset of the first symptom with clinical evidence of limb muscle atrophy and weakness.\n* Subjects taking Riluzo... | {
"compound": "SB-509",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT01933321 | Effect of Intrathecal Administration of Hematopoietic Stem Cells in Patients With Amyotrophic Lateral Sclerosis (ALS) | PHASE2, PHASE3 | COMPLETED | INTERVENTIONAL | false | Hospital Universitario Dr. Jose E. Gonzalez | Autologous cell therapy in patients with ALS can stimulate neuroplasticity, modifying the neurodegenerative process and stops the clinical progression of disease. | [
{
"type": "BIOLOGICAL",
"name": "Intrathecal autologous stem cell"
}
] | 2012-09 | https://clinicaltrials.gov/study/NCT01933321 | [
"neuroplasticity"
] | [
{
"facility": "Servicio Hematología Hospital Universitario",
"city": "Monterrey",
"state": "Nuevo León",
"country": "Mexico",
"status": "",
"lat": 25.68435,
"lon": -100.31721
}
] | {
"criteria": "Inclusion Criteria:\n\n* patients with a confirmed diagnosis of ALS according to El Escorial criteria. Diagnosis-time less than four years.\n* Over 18 years old. Forced vital capacity ≥ 40%.\n* One year of evolution.\n* Adequate nutritional state\n\nExclusion Criteria:\n\n* Severe bulbar ALS involucre.... | {
"compound": "Intrathecal autologous stem cell",
"targeting_mechanism": "Autologous hematopoietic stem cells to stimulate neuroplasticity and support degenerating motor neurons.",
"targeting_mechanism_pmid": "32043626",
"animal_results": "Preclinical stem cell studies in mouse and rat ALS models expressing mut... | ||
NCT04454840 | Treatment of Intravenous Infusion Plasma in Amyotrophic Lateral Sclerosis | EARLY_PHASE1 | COMPLETED | INTERVENTIONAL | false | Peking University Third Hospital | To evaluate the safety and effectiveness of intravenous infusion of plasma from healthy young people for the treatment of amyotrophic lateral sclerosis. | [
{
"type": "BIOLOGICAL",
"name": "Plasma from healthy young people treatment + Riluzole"
},
{
"type": "DRUG",
"name": "Riluzole"
}
] | 2016-05-01 | https://clinicaltrials.gov/study/NCT04454840 | [
"plasma_factors_rejuvenation_factors"
] | [
{
"facility": "Peking University Third Hospital",
"city": "Beijing",
"state": "",
"country": "China",
"status": "",
"lat": 39.9075,
"lon": 116.39723
}
] | {
"criteria": "Inclusion Criteria:\n\n* Meet the following diagnosis standard: confirmed, proposed and laboratory supported diagnosis;\n* Age 50-70 years old ;\n* 3-18 months course of disease;\n* Forced vital capacity (FVC) ≥70% predicted value;\n* Total amyotrophic lateral sclerosis Functional Rating Scale score ≥3... | {
"compound": "Plasma from healthy young people",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT04204889 | Trial of Oxaloacetate in ALS | PHASE1 | COMPLETED | INTERVENTIONAL | false | Omar Jawdat | The purpose of this study is to determine the safety and the maximal tolerated dose of Oxaloacetate (OAA) in patients with Amyotrophic Lateral Sclerosis (ALS). | [
{
"type": "DRUG",
"name": "Oxaloacetic Acid"
}
] | 2020-03-17 | https://clinicaltrials.gov/study/NCT04204889 | [
"mitochondrial_metabolism"
] | [
{
"facility": "University of Kansas Medical Center",
"city": "Kansas City",
"state": "Kansas",
"country": "United States",
"status": "",
"lat": 39.11417,
"lon": -94.62746
}
] | {
"criteria": "Inclusion Criteria:\n\n* A clinical diagnosis by a study investigator of laboratory-supported probable, probable, or definite ALS, according to the modified El Escorial criteria\\[1\\]\n* Vital capacity (VC) greater or equal to 50% of predicted\n* Diagnosis with ALS within 3 years prior to enrollment\n... | {
"compound": "Oxaloacetic Acid",
"targeting_mechanism": "Oxaloacetate restores mitochondrial bioenergetic function to address mitochondrial dysfunction in ALS motor neurons.",
"targeting_mechanism_pmid": "33398403",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"re... | ||
NCT00214110 | Tamoxifen Therapy in Amyotrophic Lateral Sclerosis [ALS] | PHASE2 | COMPLETED | INTERVENTIONAL | false | University of Wisconsin, Madison | This is a single-center, phase 2 randomized clinical trial of tamoxifen on mean percent predicted isometric muscle strength in patients with amyotrophic lateral sclerosis (ALS). The purpose is to determine whether the triphenylethylenetamoxifen, used as adjuvant therapy in the treatment of breast cancer, can delay the ... | [
{
"type": "DRUG",
"name": "Tamoxifen"
}
] | 2001-01 | https://clinicaltrials.gov/study/NCT00214110 | [
"Estrogen receptor"
] | [
{
"facility": "University of Wisconsin",
"city": "Madison",
"state": "Wisconsin",
"country": "United States",
"status": "",
"lat": 43.07305,
"lon": -89.40123
}
] | {
"criteria": "Inclusion Criteria:\n\n* clinically probable-laboratory supported, clinically probable, or clinically definite amyotrophic lateral sclerosis\n\nExclusion Criteria:\n\n* Allergic or idiosyncratic response to tamoxifen.\n* Other active neurologic diseases that may produce weakness, sensory loss, or auton... | {
"compound": "Tamoxifen",
"targeting_mechanism": "Stabilization of neuromuscular junctions through modulation of estrogen signaling.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "breast cancer",
"repurposed_from_pmid": "32481440"
} | ||
NCT04632225 | Safety of Engensis in Participants With Amyotrophic Lateral Sclerosis | PHASE2 | COMPLETED | INTERVENTIONAL | false | Helixmith Co., Ltd. | The purpose of this study was to evaluate the safety of intramuscular administration of Engensis in Participants with Amyotrophic Lateral Sclerosis as compared to Placebo. Safety will be assessed by incidences of treatment-emergent adverse events, treatment-emergent serious adverse events, injection site reactions and ... | [
{
"type": "BIOLOGICAL",
"name": "Engensis"
},
{
"type": "OTHER",
"name": "Placebo"
}
] | 2021-03-09 | https://clinicaltrials.gov/study/NCT04632225 | [
"engensis"
] | [
{
"facility": "St. Joseph's Hospital and Medical Center, Barrows Neurological Institute",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "Northwestern University",
"city": "Chicago",
"st... | {
"criteria": "Inclusion Criteria:\n\n1. Clinically definite or probable Amyotrophic Lateral Sclerosis or laboratory-supported probable Amyotrophic Lateral Sclerosis as defined in the revised El Escorial/Airlie House diagnostic criteria\n2. The site of onset of Amyotrophic Lateral Sclerosis symptoms is a limb and exp... | {
"compound": "Engensis",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT04240925 | Tolerability, Safety and Efficacy of Sigh Breaths During NIMV in Motor Neuron Disease | NA | UNKNOWN | INTERVENTIONAL | false | Ospedale San Raffaele | Non-invasive mechanical ventilation (NIMV) is the recommended standard of care as initial therapy for patients with motor neuron disease (MND) with deterioration of the respiratory function.
SIGH\_01 study is aimed at investigating the tolerability, safety profile and efficacy of sigh breaths during non-invasive mecha... | [
{
"type": "DEVICE",
"name": "NIMV with sigh breaths"
},
{
"type": "DEVICE",
"name": "Standard NIMV"
}
] | 2018-05-25 | https://clinicaltrials.gov/study/NCT04240925 | [] | [
{
"facility": "Ospedale San Raffaele",
"city": "Milan",
"state": "",
"country": "Italy",
"status": "",
"lat": 42.78235,
"lon": 12.59836
}
] | {
"criteria": "Inclusion Criteria:\n\n* Willing and able to give informed consent\n* MND diagnosis according to El-Escorial criteria\n* Non-invasive ventilation indications in accordance with the international guidelines\n\nExclusion Criteria:\n\n* Inability to adhere to study visit schedule or lack of reliable caret... | {
"compound": "unknown",
"targeting_mechanism": "Non-invasive mechanical ventilation with sigh breaths to support respiratory function in motor neuron disease.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pm... | ||
NCT03334786 | Study to Evaluate Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Appendicular Muscle in Adult Subjects With ALS | PHASE1, PHASE2 | TERMINATED | INTERVENTIONAL | false | Flex Pharma, Inc. | The FLX-787-107 study will determine how well FLX-787-ODT works to reduce fasciculations in patients with Amyotrophic Lateral Sclerosis (ALS). The study will measure how often fasciculations occur, if tongue and muscle strength, speech, and swallowing are affected, and monitor any side effects that might develop while ... | [
{
"type": "DRUG",
"name": "FLX-787-ODT"
}
] | 2018-04-05 | https://clinicaltrials.gov/study/NCT03334786 | [
"Sodium channel"
] | [
{
"facility": "Beth Israel Deaconess Medical Center",
"city": "Boston",
"state": "Massachusetts",
"country": "United States",
"status": "",
"lat": 42.35843,
"lon": -71.05977
}
] | {
"criteria": "Inclusion Criteria:\n\n* Documented diagnosis of ALS diagnosis of less than 5 years.\n* Greater than 6 fasciculations per minute noted at least in the tongue by clinical, ultrasound, or EMG evaluation.\n* Normal oral cavity exam at screening.\n\nExclusion Criteria:\n\n* Presence of clinically significa... | {
"compound": "FLX-787-ODT",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT05163886 | Study of Safety, Tolerability, and Biological Activity of LAM-002A in C9ORF72-Associated Amyotrophic Lateral Sclerosis | PHASE2 | COMPLETED | INTERVENTIONAL | false | OrphAI Therapeutics | This is a clinical trial to evaluate the safety, tolerability, and biological effect of LAM-002A in adults with C9ORF72-associated ALS (C9ALS). | [
{
"type": "DRUG",
"name": "LAM-002A"
},
{
"type": "OTHER",
"name": "Placebo"
}
] | 2021-12-23 | https://clinicaltrials.gov/study/NCT05163886 | [
"C9orf72"
] | [
{
"facility": "University of Iowa Hospitals and Clinics",
"city": "Iowa City",
"state": "Iowa",
"country": "United States",
"status": "",
"lat": 41.66113,
"lon": -91.53017
},
{
"facility": "Johns Hopkins University School of Medicine",
"city": "Baltimore",
"state": "Maryl... | {
"criteria": "Inclusion Criteria:\n\n1. Diagnosis of C9ORF72-associated ALS with BOTH of the following:\n\n 1. Documentation of a clinical genetic test demonstrating the presence of a pathogenic repeat expansion in C9ORF72. If there is a strong clinical suspicion for C9ALS based on C9-positive family history and E... | {
"compound": "LAM-002A",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT05619783 | Extension Study Evaluating The Safety And Tolerability of AMX0035 | PHASE3 | COMPLETED | INTERVENTIONAL | false | Amylyx Pharmaceuticals Inc. | The primary objective is to evaluate the safety and tolerability of AMX0035 over 108 weeks of open label treatment for participants previously enrolled in Study A35-004 (PHOENIX). | [
{
"type": "DRUG",
"name": "AMX0035"
}
] | 2022-12-29 | https://clinicaltrials.gov/study/NCT05619783 | [
"TARDBP"
] | [
{
"facility": "University Hospitals Leuven",
"city": "Leuven",
"state": "",
"country": "Belgium",
"status": "",
"lat": 50.87959,
"lon": 4.70093
},
{
"facility": "Hospices Civils de Lyon Hôpital Neurologique Pierre Wertheimer Cellule Mutualisée de Recherche Clinique (CMRC)",
"... | {
"criteria": "Inclusion Criteria:\n\n1. Previous participation in Study A35-004 (PHOENIX), including completion of the randomized controlled phase through Week 48 (this timepoint may be upcoming at the time of screening). Participants who do not complete randomized-controlled phase through Week 48 for medical reason... | {
"compound": "AMX0035",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT02418546 | Electronic-health Application To Measure Outcomes REmotely Clinical Trial | NA | COMPLETED | INTERVENTIONAL | false | Massachusetts General Hospital | This is a phase II feasibility, safety, tolerability and preliminary efficacy study of an e-Health application versus in-person nutritional counseling to maintain or increase weight in patients with neurodegenerative diseases including amyotrophic lateral sclerosis (ALS), Parkinson's Disease (PD) and Huntington's disea... | [
{
"type": "BEHAVIORAL",
"name": "In-Person Nutritional Counseling by a Registered Dietitian"
},
{
"type": "BEHAVIORAL",
"name": "Nutritional counseling using an e-Health Application"
}
] | 2015-04 | https://clinicaltrials.gov/study/NCT02418546 | [
"nutritional_status"
] | [
{
"facility": "Massachusetts General Hospital",
"city": "Boston",
"state": "Massachusetts",
"country": "United States",
"status": "",
"lat": 42.35843,
"lon": -71.05977
}
] | {
"criteria": "Inclusion Criteria:\n\n1. Adults with neurodegenerative diseases such as ALS, PD or HD with or without a history of unintentional weight loss.\n2. Male or female subjects aged 18 years or older.\n3. Participants must be capable of providing informed consent and complying with trial procedures.\n4. Part... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT06493279 | Evaluate the Safety and Efficacy of Intrathecal Injection of RJK002 in Patients With Amyotrophic Lateral Sclerosis | PHASE1 | ACTIVE_NOT_RECRUITING | INTERVENTIONAL | false | RJK Biopharma Ltd | The goal of the study aims to evaluate the safety and tolerability of a single intrathecal injection of RJK002 in subjects with amyotrophic lateral sclerosis (ALS), and to determine the recommended Phase II dose (RP2D). | [
{
"type": "DRUG",
"name": "RJK002 Intrathecal injection"
}
] | 2024-09-24 | https://clinicaltrials.gov/study/NCT06493279 | [
"ATXN2"
] | [
{
"facility": "Peking University Third Hospital",
"city": "Beijing",
"state": "",
"country": "China",
"status": "",
"lat": 39.9075,
"lon": 116.39723
}
] | {
"criteria": "Main Inclusion Criteria:\n\n1. Female or male subjects who are ≥ 18 years of age at screening;\n2. Patients with a diagnosis consistent with clinically or laboratory-supported possible, probable, or definite sporadic or familial ALSALS in accordance with Revised EI Escorial diagnostic criteria publishe... | {
"compound": "RJK002",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT07407725 | Clinical Outcome Assessment for AT & BCI | NA | RECRUITING | INTERVENTIONAL | false | Shirley Ryan AbilityLab | Many individuals with severe motor impairments rely on Assistive Technologies (ATs) or Brain-Computer Interfaces (BCIs) to interact with digital devices such as their computers. Clinicians and researchers currently lack a common framework to objectively quantify how much a given AT or BCI improves real-world function o... | [
{
"type": "DEVICE",
"name": "Eye Tracker"
},
{
"type": "DEVICE",
"name": "Mouth Operated Joystick"
},
{
"type": "DEVICE",
"name": "Non-invasive electroencephalogram (EEG) Headset"
},
{
"type": "DEVICE",
"name": "Implantable Brain-Computer-Interface"
},
{
"type": "... | 2026-01-08 | https://clinicaltrials.gov/study/NCT07407725 | [] | [
{
"facility": "Shirley Ryan AbilityLab",
"city": "Chicago",
"state": "Illinois",
"country": "United States",
"status": "RECRUITING",
"lat": 41.85003,
"lon": -87.65005
}
] | 312-238-6875 | ajayaraman@sralab.org | {
"criteria": "Enrollment will involve three different cohorts, namely a cohort of healthy participant, a cohort of ALS/SCI participant who underwent the implant of an invasive BCI device, and a cohort of ALS/SCI participants without any implanted BCI device.\n\nBelow are listed the inclusion and exclusion criteria f... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT02789059 | Muscle Oxygenation in Effort in Neuromuscular Diseases | NA | COMPLETED | INTERVENTIONAL | false | University Hospital, Lille | Previous studies showed modifications of muscle oxygenation parameters in muscular dystrophies du to an impairment or an absence of dystrophin.
Our study aim at assessing muscle oxygenation during effort in different neuromuscular diseases (muscular dystrophies related and not related to dystrophin, non dystrophic myo... | [
{
"type": "OTHER",
"name": "muscle oxygenation"
}
] | 2015-07-02 | https://clinicaltrials.gov/study/NCT02789059 | [
"muscle_oxygenation"
] | [
{
"facility": "Hôpital Amiens Nord, Service de Neurologie",
"city": "Amiens",
"state": "",
"country": "France",
"status": "",
"lat": 49.9,
"lon": 2.3
},
{
"facility": "CHRU de Lille, Hôpital Swyngedhauw",
"city": "Lille",
"state": "",
"country": "France",
"status"... | {
"criteria": "Inclusion Criteria:\n\n* healthy subjects and\n* subjects affected by one of the fallowing neuromuscular diseases: Becker Muscular dystrophy Facioscapulohumeral dystrophy, Limb Girdle Muscular Dystrophy , Congenital Myopathy , Spinal Muscular Atrophy Charcot Marie Tooth Disease and Amyotrophic Lateral ... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT04176224 | Clinical Pharmacology Study of Oral Edaravone in Patients With Amyotrophic Lateral Sclerosis | PHASE1 | COMPLETED | INTERVENTIONAL | false | Shionogi | To evaluate the pharmacokinetics of single doses of edaravone oral suspension in Patients with Amyotrophic Lateral Sclerosis | [
{
"type": "DRUG",
"name": "MT-1186"
}
] | 2019-04-17 | https://clinicaltrials.gov/study/NCT04176224 | [
"oxidative_stress"
] | [
{
"facility": "Investigational site",
"city": "Tokyo",
"state": "",
"country": "Japan",
"status": "",
"lat": 35.6895,
"lon": 139.69171
}
] | {
"criteria": "Inclusion Criteria:\n\nThe key criteria are listed below.\n\n* Patients aged between 20 and 75 years at the time of informed consent\n* Japanese patients\n* Among patients with ALS, those \"Clinically definite ALS,\" \"Clinically probable ALS\" or \"Clinically probable-laboratory-supported ALS\" accord... | {
"compound": "MT-1186 (edaravone)",
"targeting_mechanism": "Edaravone is a free radical scavenger that reduces oxidative stress by neutralizing reactive oxygen species.",
"targeting_mechanism_pmid": "38473944",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurpo... | ||
NCT06215391 | Customized Masks in Non-Invasive Mechanical Ventilation | NA | UNKNOWN | INTERVENTIONAL | false | Hospital Universitario 12 de Octubre | In non-invasive mechanical ventilation (NIMV), the interface is the primary determinant of success, as adherence and quality of therapy mainly depend on it. The aim of this study is to investigate the usefulness of a customised mask approach to minimise leakage and upper airway obstruction. It will focus on ventilator ... | [
{
"type": "DEVICE",
"name": "3d printed mask"
}
] | 2023-12-10 | https://clinicaltrials.gov/study/NCT06215391 | [] | [
{
"facility": "Hospital Universitarios 12 de Octubre",
"city": "Madrid",
"state": "Madrid",
"country": "Spain",
"status": "RECRUITING",
"lat": 40.4165,
"lon": -3.70256
}
] | 913908492 | lauragramos@hotmail.es | {
"criteria": "Inclusion Criteria:\n\n* Patient enrolled in the Home Mechanical Ventilation (HMV) program.\n* Adherence of \\>4 hours per day.\n* In the case of COPD, inspiratory pressures \\>18 cmH2O.\n* Users of a Resmed HMV device to standardize and facilitate the analysis of the respirator log.\n* Commercial mask... | {
"compound": "3D printed mask",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT04667013 | A Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of TBN | PHASE1 | NOT_YET_RECRUITING | INTERVENTIONAL | false | Guangzhou Magpie Pharmaceuticals Co., Ltd. | The purpose of this study is to assess the safety, tolerability and pharmacokinetics (i.e. how study drug is taken up by the body) of TBN in healthy participants. | [
{
"type": "DRUG",
"name": "Tetramethylpyrazine nitrone (TBN) tablet / Placebo"
}
] | 2028-09-01 | https://clinicaltrials.gov/study/NCT04667013 | [
"oxidative_stress"
] | [] | 305-547-5857 | david.wyatt@syneoshealth.com | {
"criteria": "Inclusion Criteria:\n\n1. Male or non-childbearing potential female, non-smoker (no use of tobacco or nicotine products within 3 months prior to screening), ≥ 18 and ≤ 50 years of age, with BMI \\> 18.0 and \\< 30.0 kg/m2 and body weight ≥ 50.0 kg for males and ≥ 45.0 kg for females.\n2. Healthy as def... | {
"compound": "Tetramethylpyrazine nitrone (TBN)",
"targeting_mechanism": "Tetramethylpyrazine nitrone activates the PGC-1alpha/Nrf2/HO-1 pathway to reduce oxidative stress and improve mitochondrial function in ALS.",
"targeting_mechanism_pmid": "33152451",
"animal_results": "TBN improves motor dysfunction and ... |
NCT05299658 | An Open-Label Extension for the Phase 2 Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Catalysis With CNM-Au8 to Slow Disease Progression in ALS | PHASE2 | ACTIVE_NOT_RECRUITING | INTERVENTIONAL | false | Clene Nanomedicine | This is an optional open-label extension to participants that have completed the clinical trial CNMAu8.205. | [
{
"type": "DRUG",
"name": "CNMAu8"
}
] | 2021-11-13 | https://clinicaltrials.gov/study/NCT05299658 | [
"bioenergetics"
] | [
{
"facility": "Concord Hospital",
"city": "Concord",
"state": "New South Wales",
"country": "Australia",
"status": "",
"lat": -33.84722,
"lon": 151.10381
},
{
"facility": "Neuroscience Research Australia",
"city": "Randwick",
"state": "New South Wales",
"country": "Au... | {
"criteria": "Inclusion Criteria:\n\n1. Participants must have completed the randomized placebo-controlled Treatment Period without compliance issues.\n2. Able to understand and give written informed consent to participate in the open-label extension.\n3. If referred from a third party (neurologist or a State based ... | {
"compound": "CNM-Au8",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT02670226 | Muscular Biomarkers in Amyotrophic Lateral Sclerosis | NA | COMPLETED | INTERVENTIONAL | false | University Hospital, Tours | The first objective is to find some biomarkers, or a profile of biomarkers of ALS to help to diagnosis. The second objective is to better understand the pathogenesis of this disease by the exploration of muscle, blood and satellite cells metabolomes and transcriptomes. | [
{
"type": "OTHER",
"name": "Samples"
}
] | 2016-03-29 | https://clinicaltrials.gov/study/NCT02670226 | [] | [
{
"facility": "Service de chirurgie orthopédique et traumatologique, CHRU de TOURS",
"city": "Tours",
"state": "",
"country": "France",
"status": "",
"lat": 47.39484,
"lon": 0.70398
},
{
"facility": "Service de Neurologie, CHRU de TOURS",
"city": "Tours",
"state": "",
... | {
"criteria": "Case group selection criteria:\n\nInclusion Criteria:\n\n* Age ≥ 18 years and ≥ 75 years\n* ALS according to the El Escorial criteria\n* Patients affiliated to social security scheme\n* Informed consent signed by the patient\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women\n* Contraindicatio... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT02537132 | "New Perspectives of Adaptation to NIV in ALS" | NA | COMPLETED | INTERVENTIONAL | false | Fondazione Don Carlo Gnocchi ETS | The purpose of this study is to demonstrate that the adaptation to the Non Invasive Ventilation (NIV) at home is not worse when compared with an adaptation performed in inpatient settings. | [
{
"type": "OTHER",
"name": "Adaptation and training to Non Invasive Ventilation (NIV)"
}
] | 2015-01 | https://clinicaltrials.gov/study/NCT02537132 | [] | [
{
"facility": "Michele Vitacca",
"city": "Lumezzane",
"state": "Brescia",
"country": "Italy",
"status": "",
"lat": 45.64789,
"lon": 10.26487
},
{
"facility": "Paolo Banfi",
"city": "Milan",
"state": "",
"country": "Italy",
"status": "",
"lat": 45.46427,
"l... | {
"criteria": "Inclusion Criteria:\n\n* ALS diagnosis according to the criteria of El Escorial;\n* Clinical indication to NIV (nocturnal hypoventilation and respiratory muscle weakness confirmed according to the criteria normally accepted);\n* No respiratory infection within 3 months\n* Severe disability (ALS-FRS \\<... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT04993755 | A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD | PHASE2 | COMPLETED | INTERVENTIONAL | false | Transposon Therapeutics, Inc. | This is a Phase 2a study to assess the the safety and tolerability of TPN-101 in patients with Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD) Associated with Hexanucleotide Repeat Expansion in the C9orf72 gene (C9ORF72 ALS/FTD). | [
{
"type": "DRUG",
"name": "TPN-101, 400 mg/day"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2021-10-01 | https://clinicaltrials.gov/study/NCT04993755 | [
"C9orf72"
] | [
{
"facility": "University of California San Diego",
"city": "La Jolla",
"state": "California",
"country": "United States",
"status": "",
"lat": 32.84727,
"lon": -117.2742
},
{
"facility": "University of California Irvine - ALS & Neuromuscular Center",
"city": "Orange",
"s... | {
"criteria": "Inclusion Criteria:\n\n* Documentation of a clinical genetic test demonstrating a hexanucleotide repeat expansion (HRE) in the C9orf72 gene\n* Has a reliable caregiver/informant to accompany the patient to all study visits\n\nFor patients with ALS (with or without FTD):\n\n* Diagnosis of ALS (probable,... | {
"compound": "TPN-101",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT06710626 | Control of Assistive Devices Via Brain-Computer Interface Technology | NA | ENROLLING_BY_INVITATION | INTERVENTIONAL | false | Neuralink Corp | The CONVOY Study is a clinical trial designed to explore the feasibility of participants from the PRIME Study (NCT06429735) using the N1 Implant to control various assistive devices. The main goal is to determine whether participants can successfully modulate their brain activity to control devices, such as an Assistiv... | [
{
"type": "DEVICE",
"name": "Assistive Robotic Arm"
}
] | 2024-11-25 | https://clinicaltrials.gov/study/NCT06710626 | [] | [
{
"facility": "Barrow Neurological Institute",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
}
] | {
"criteria": "Inclusion Criteria:\n\n* Continued enrollment in the PRIME Study.\n* Implanted with the N1 Implant.\n\nExclusion Criteria:\n\n* Explantation or deactivation of the N1 Implant.\n* Insufficient N1 Implant BCI performance demonstrated.\n* Lack of a suitable physical space to perform research sessions.\n* ... | {
"compound": "N1 Implant and Assistive Robotic Arm",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT04302870 | Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial | PHASE2, PHASE3 | RECRUITING | INTERVENTIONAL | false | University of Edinburgh | MND-SMART is investigating whether selected drugs can slow down the progression of motor neuron disease (MND) and improve survival.
The study is 'multi-arm' meaning more than one treatment will be tested at the same time. The trial started with 3 arms; drug 1 (memantine), drug 2 (trazodone) and placebo (dummy drug). A... | [
{
"type": "DRUG",
"name": "Memantine Hydrochloride Oral Solution"
},
{
"type": "DRUG",
"name": "Trazodone Hydrochloride oral solution"
},
{
"type": "DRUG",
"name": "Placebo oral solution"
},
{
"type": "DRUG",
"name": "Amantadine Hydrochloride Oral Solution"
},
{
"... | 2020-02-27 | https://clinicaltrials.gov/study/NCT04302870 | [
"nmda_receptor_antagonism",
"serotonin_modulation",
"calcineurin_inhibition"
] | [
{
"facility": "Southern Health and Social Care Trust, Craigavon Area Hospital",
"city": "Portadown",
"state": "County Armagh",
"country": "United Kingdom",
"status": "RECRUITING",
"lat": 54.42302,
"lon": -6.44434
},
{
"facility": "Aberdeen Royal Infirmary",
"city": "Aberdeen"... | 0131 465 9612 | siddharthan.chandran@ed.ac.uk | {
"criteria": "Participants will be considered eligible for randomisation if they fulfil all the core inclusion criteria and none of the exclusion criteria as defined below. In addition, investigators must simultaneously check and ensure participants do not meet any of the drug specific exclusion criteria. If exclusi... | {
"compound": "Memantine Hydrochloride, Trazodone Hydrochloride, Amantadine Hydrochloride, Tacrolimus",
"targeting_mechanism": "Amantadine is a weak NMDA receptor antagonist that increases dopamine release and blocks dopamine reuptake",
"targeting_mechanism_pmid": "37166702",
"animal_results": "unknown",
"ani... |
NCT07017946 | Intestinal Microbiome Transplant in ALS | PHASE1, PHASE2 | RECRUITING | INTERVENTIONAL | false | Duke University | This is a 24-week study of intestinal microbiome transplant in people with ALS. All participants will be evaluated clinically in person for 4 visits. Blood and mailed/ fresh stool samples will also be collected. Blood samples will be used to determine changes in neurofilament light chain over time. Stool samples will b... | [
{
"type": "DRUG",
"name": "MTP-101C"
}
] | 2026-01-27 | https://clinicaltrials.gov/study/NCT07017946 | [
"microbiome"
] | [
{
"facility": "Duke University Medical Center",
"city": "Durham",
"state": "North Carolina",
"country": "United States",
"status": "RECRUITING",
"lat": 35.99403,
"lon": -78.89862
}
] | 919-613-2681 | ALSresearch@duke.edu | {
"criteria": "Inclusion Criteria:\n\n* Diagnosis of ALS according to Gold Coast Criteria\n* Age: 18+ years at enrollment\n* Fast-progressing (ALSFRS-R change of at least 1.5 points per month between last 2 measurements at screening)\n* Modestly but not severely affected (ALSFRS-R score at or above 24 at screening)\n... | {
"compound": "MTP-101C",
"targeting_mechanism": "Microbiome-based therapeutic targeting gut dysbiosis to restore healthy gut microbiota composition and alleviate neurodegenerative disease progression through neuroimmune mechanisms",
"targeting_mechanism_pmid": "32503641",
"animal_results": "unknown",
"animal... |
NCT07595666 | Comparison of NeuroEXPLORER PET/CT Versus Standard-of-care PET/CT of the Head and Neck Region. | NA | ENROLLING_BY_INVITATION | INTERVENTIONAL | false | prof. dr. Koen Van Laere | The goal of this clinical study is to compare the current standard-of-care PET/CT scanner with the new NeuroEXPLORER PET/CT, with the aim of demonstrating the added diagnostic value of the new scanner. As this is the first device of its kind in Europe, the study will also evaluate the safety and general feasibility of ... | [
{
"type": "DEVICE",
"name": "Standard-of-care PET/CT"
},
{
"type": "DEVICE",
"name": "NeuroEXPLORER"
}
] | 2025-09-30 | https://clinicaltrials.gov/study/NCT07595666 | [] | [
{
"facility": "UZ Leuven",
"city": "Leuven",
"state": "Vlaams-Brabant",
"country": "Belgium",
"status": "",
"lat": 50.87959,
"lon": 4.70093
}
] | {
"criteria": "Inclusion Criteria:\n\n* All subjects referred for standard-of-care PET in the indications for the substudies are eligible.\n\nExclusion Criteria:\n\n* Subject is unwilling to avoid unusual, unaccustomed, or strenuous physical activity beginning 4 days prior to tracer injection up to 1 day after tracer... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT06903286 | Extension Study of Participants From SPG302-ALS-001 | PHASE2 | TERMINATED | INTERVENTIONAL | false | Spinogenix | This study will evaluate the long-term safety and efficacy of participants enrolled in SPG302-ALS-101 with Amyotrophic Lateral Sclerosis (ALS) | [
{
"type": "DRUG",
"name": "SPG302"
}
] | 2025-05-29 | https://clinicaltrials.gov/study/NCT06903286 | [
"SMN1"
] | [
{
"facility": "Macquarie University",
"city": "North Ryde",
"state": "New South Wales",
"country": "Australia",
"status": "",
"lat": -33.79677,
"lon": 151.12436
},
{
"facility": "Royal Brisbane and Women's Hospital",
"city": "Herston",
"state": "Queensland",
"country"... | {
"criteria": "Inclusion Criteria:\n\n• Must have participated in all study activities of SPG302-ALS-001, the parent study\n\nExclusion Criteria:\n\n* Unable to reliably and regularly swallow whole oral medications on a daily basis.\n* Medical conditions that investigator or sponsor determine would interfere with par... | {
"compound": "SPG302",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT02665663 | Tongue Strength in Amyotrophic Lateral Sclerosis (ALS) | NA | UNKNOWN | INTERVENTIONAL | false | Assistance Publique Hopitaux De Marseille | Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease with a poor prognosis that occurs in adults 64 years on average. Its prevalence is 4 to 6/100 000 inhabitants.
Swallowing disorders occur during evolution and involve the prognosis of patients in the short term by the association of dysphagia with seve... | [
{
"type": "DEVICE",
"name": "medical device"
}
] | 2016-02 | https://clinicaltrials.gov/study/NCT02665663 | [] | [
{
"facility": "Service ORL Assistance Publique Hôpitaux de Marseille",
"city": "Marseille",
"state": "",
"country": "France",
"status": "",
"lat": 43.29695,
"lon": 5.38107
}
] | 04 91 38 60 71 | aude.lagier@ap-hm.fr | {
"criteria": "Inclusion Criteria:\n\n* Adults and legally responsible/ valid medical insurance\n* patients : ALS diagnostic already announced\n* healthy subjects : EAT-10 score\\<2\n\nExclusion Criteria:\n\n* Non pregnant and non baby feeding\n* Presence of risk factor or suspicion of Creutzfeld Jacob Disease\n* All... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT06008249 | Platform Trial to Assess the Efficacy of Multiple Drugs in Amyotrophic Lateral Sclerosis (ALS) | PHASE3 | TERMINATED | INTERVENTIONAL | false | Stichting TRICALS Foundation | The objective of this phase III, placebo-controlled platform study is to investigate the efficacy of drugs for patients with ALS (Amyotrophic lateral sclerosis). | [
{
"type": "DRUG",
"name": "Lithium Carbonate 400 MG"
}
] | 2021-08-09 | https://clinicaltrials.gov/study/NCT06008249 | [
"Glycogen synthase kinase-3"
] | [
{
"facility": "Flinders Medical Centre",
"city": "Adelaide",
"state": "",
"country": "Australia",
"status": "",
"lat": -34.92866,
"lon": 138.59863
},
{
"facility": "Royal Brisbane and Women's Hospital",
"city": "Brisbane",
"state": "",
"country": "Australia",
"sta... | {
"criteria": "Inclusion Criteria:\n\n1. ≥ 18 years at the time of screening.\n2. Diagnosis of ALS according to the revised El Escorial criteria (possible, probable-laboratory supported, probable or definite).\n3. Capable of providing informed consent and complying with trial procedures, including randomization to su... | {
"compound": "Lithium Carbonate",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT04950933 | The Treatment of Amyotrophic Lateral Sclerosis With Huollingshengji Granules | PHASE2, PHASE3 | UNKNOWN | INTERVENTIONAL | false | Peking University Third Hospital | This study intends to evaluate the efficacy and safety of Dong Lingsheng Ji Granule in the treatment of amyotrophic lateral sclerosis (spleen deficiency, kidney-yang deficiency syndrome) in comparison with riluzole, so as to provide data support for marketing application or subsequent clinical research design. | [
{
"type": "DRUG",
"name": "Huolingshengji Granules"
},
{
"type": "DRUG",
"name": "Riluzole tablet"
}
] | 2020-06-01 | https://clinicaltrials.gov/study/NCT04950933 | [
"riluzole"
] | [
{
"facility": "Peking University Third Hospital",
"city": "Beijin",
"state": "",
"country": "China",
"status": "RECRUITING",
"lat": 35.93305,
"lon": 111.40836
}
] | +86 13701023871 | dsfan@sina.com | {
"criteria": "Inclusion Criteria:\n\n1. Meet the Western diagnostic criteria for amyotrophic lateral sclerosis (ALS) (clinically confirmed ALS, clinically likely ALS or clinically likely ALS- laboratory support);\n2. The score of the modified amyotrophic lateral sclerosis function scale (ALSFRS-R) was ≥2 points for ... | {
"compound": "Huolingshengji Granules",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT07341984 | A Physiotherapy Intervention Study in Patients With Amyotrophic Lateral Sclerosis (ALS) | NA | RECRUITING | INTERVENTIONAL | false | Charlotte Vogt | This study investigates whether an individualized physiotherapy program, tailored to each patient's specific motor deficits, can better support physical function compared with usual care physiotherapy in people with ALS.
The individualized program is guided by diagnostic assessments using a robotic leg press system, w... | [
{
"type": "OTHER",
"name": "Individualized Physiotherapy"
}
] | 2025-12-16 | https://clinicaltrials.gov/study/NCT07341984 | [] | [
{
"facility": "ALS Clinic",
"city": "Sankt Gallen",
"state": "",
"country": "Switzerland",
"status": "RECRUITING",
"lat": 47.42391,
"lon": 9.37477
}
] | 0041714943581 | charlotte.vogt@h-och.ch | {
"criteria": "Inclusion Criteria:\n\n* diagnosis of clinically probable, probable laboratory-supported, or definite ALS (revised El Escorial criteria) or upper motor neuron only (OPM classification \\[onset, propagation, motoneuron involvement\\])\n* age ≥18 years; ability to understand study information and provide... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT00839033 | Evaluation of a Mechanical Device During Acute Respiratory Failure in Patients With Neuromuscular Disorders | PHASE3 | TERMINATED | INTERVENTIONAL | false | Assistance Publique - Hôpitaux de Paris | The hypothesis is that a mechanical insufflation-exsufflation (MI-E) is associated with a decrease in the number of intubations and more rapid clinical improvement in children and adults with neuromuscular disease who are admitted for an acute respiratory exacerbation.In this prospective, randomised, multicenter study,... | [
{
"type": "DEVICE",
"name": "mechanical insufflation - exsufflation"
},
{
"type": "DEVICE",
"name": "Standard respiratory physiotherapy"
}
] | 2009-06 | https://clinicaltrials.gov/study/NCT00839033 | [] | [
{
"facility": "Hospital Armand Trousseau, Pediatric Pulmonology Department and INSERM UMR S-893",
"city": "Paris",
"state": "",
"country": "France",
"status": "",
"lat": 48.85341,
"lon": 2.3488
}
] | {
"criteria": "Inclusion Criteria:\n\nPediatric or adult patients with chronic neuromuscular disorders, such as spinal muscular atrophy, Duchenne muscular dystrophy, other congenital myopathy, or amyotrophic lateral sclerosis (ALS), hospitalized for acute respiratory failure, as defined by:\n\n* Persistent bronchial ... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT00047723 | Minocycline to Treat Amyotrophic Lateral Sclerosis | PHASE3 | COMPLETED | INTERVENTIONAL | false | National Institute of Neurological Disorders and Stroke (NINDS) | The purpose of this trial is to test the safety, tolerability, and effectiveness of minocycline compared to placebo in patients with amyotrophic lateral sclerosis (ALS). | [
{
"type": "DRUG",
"name": "minocycline"
}
] | 2003-01 | https://clinicaltrials.gov/study/NCT00047723 | [
"neuroinflammation"
] | [
{
"facility": "Mayo Clinic",
"city": "Scottsdale",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.50921,
"lon": -111.89903
},
{
"facility": "University of California, Irvine",
"city": "Irvine",
"state": "California",
"country": "United States"... | {
"criteria": "To be eligible for enrollment in this study, subjects must meet the following eligibility criteria within fourteen days prior to randomization:\n\nInclusion criteria:\n\n* A clinical diagnosis of laboratory-supported probable, probable or definite ALS, according to modified EL Escorial criteria.\n* FVC... | {
"compound": "minocycline",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT03100110 | NeuroCognitive Communicator: Safety Study | NA | UNKNOWN | INTERVENTIONAL | false | Ottawa Hospital Research Institute | Individuals suffering from tetraplegia as a result of cervical spinal cord injury, brainstem stroke, or amyotrophic lateral sclerosis (ALS) cannot independently perform tasks of daily living. In many cases, these conditions do not have effective therapies and the only intervention is the provision of assistive devices ... | [
{
"type": "DEVICE",
"name": "NeuroCognitive Communicator"
}
] | 2019-05-13 | https://clinicaltrials.gov/study/NCT03100110 | [] | [
{
"facility": "The Ottawa Hospital",
"city": "Ottawa",
"state": "Ontario",
"country": "Canada",
"status": "RECRUITING",
"lat": 45.41117,
"lon": -75.69812
}
] | 647-563-3141 | rdoole@ohri.ca | {
"criteria": "Inclusion Criteria:\n\n* Documented diagnosis of a complete or incomplete cervical spinal cord injury, with stable neurological deficits greater than 1 year, or ALS with equivalent degree of deficit.\n* Maintain some level of communication, enough to independently provide informed consent for the study... | {
"compound": "NeuroCognitive Communicator",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT02645461 | Acetylcholine Receptors From Human Muscles as Pharmacological Target for ALS | NA | COMPLETED | INTERVENTIONAL | false | University of Roma La Sapienza | Amyotrophic lateral sclerosis (ALS) is a fatal disease leading to motor neuron degeneration and progressive paralysis. Other studies have revealed defects in skeletal muscle even in absence of motor neuron anomalies, focusing on acetylcholine receptors (AChRs) and supporting the so-called "dying-back" hypothesis. Outco... | [
{
"type": "DRUG",
"name": "endocannabinoid palmitoylethanolamide (PEA)"
},
{
"type": "DRUG",
"name": "Riluzole"
}
] | 2014-01 | https://clinicaltrials.gov/study/NCT02645461 | [
"Acetylcholine receptors",
"endocannabinoid_signaling"
] | [] | {
"criteria": "Inclusion Criteria:\n\n* Diagnosis of ALS according to the El-Escorial criteria;\n* Age\\> 18 years;\n* ALS Functional Rating Scale-Revised (ALSFRS- r) score\\> 20;\n* Forced Vital Capacity (FVC)\\> 30%;\n* Treatment with Riluzole.\n\nExclusion Criteria:\n\n* Other diseases motor neurons;\n* Experiment... | {
"compound": "palmitoylethanolamide (PEA)",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT01089010 | A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | COMPLETED | INTERVENTIONAL | false | Cytokinetics | The primary objective of this study is to demonstrate a pharmacodynamic effect of CK 2017357 on measures of skeletal muscle function or fatigability in patients with ALS. | [
{
"type": "DRUG",
"name": "Placebo"
},
{
"type": "DRUG",
"name": "250 mg CK-2017357"
},
{
"type": "DRUG",
"name": "500 mg CK-2017357"
}
] | 2010-03 | https://clinicaltrials.gov/study/NCT01089010 | [
"skeletal_muscle_function"
] | [
{
"facility": "Phoenix Neurological Associates, Ltd.",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "University Neurology Associates",
"city": "Fresno",
"state": "California",
"cou... | {
"criteria": "Inclusion Criteria\n\nFor enrollment, patients were required to satisfy all of the following criteria at baseline:\n\n1\\. Able to comprehend and willing to sign an Informed Consent Form (ICF)\n\n1. A diagnosis of familial or sporadic ALS (defined as meeting the possible, laboratory-supported probable,... | {
"compound": "CK-2017357",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT03800524 | Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS | PHASE3 | UNKNOWN | INTERVENTIONAL | false | Humanitas Mirasole SpA | This is a Phase III, multi-centre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate Safety and Efficacy of Tauroursodeoxycholic (TUDCA) as add-on Treatment in Patients Affected by Amyotrophic Lateral Sclerosis (ALS). | [
{
"type": "DRUG",
"name": "Tauroursodeoxycholic Acid"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2019-02-22 | https://clinicaltrials.gov/study/NCT03800524 | [
"apoptosis"
] | [
{
"facility": "Katholieke Universiteit Leuven",
"city": "Leuven",
"state": "",
"country": "Belgium",
"status": "",
"lat": 50.87959,
"lon": 4.70093
},
{
"facility": "Centre Hospitalier Universitaire de Bordeaux",
"city": "Bordeaux",
"state": "",
"country": "France",
... | {
"criteria": "Inclusion Criteria:\n\n* Probable laboratory-supported, probable, or definite ALS, as defined by El Escorial Revised ALS diagnostic criteria at screening visit (month -3)\n* Disease duration ≤ 18 months at screening visit (month -3)\n* Able to perform reproducible pulmonary function tests at screening ... | {
"compound": "Tauroursodeoxycholic Acid (TUDCA)",
"targeting_mechanism": "Tauroursodeoxycholic acid exhibits anti-apoptotic and neuroprotective activities against neurodegenerative diseases mediated by protein homeostasis and apoptotic pathways.",
"targeting_mechanism_pmid": "35659112",
"animal_results": "unkn... | ||
NCT03705390 | A Safety and Tolerability Study of ILB® in Patients With Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | TERMINATED | INTERVENTIONAL | false | University of Birmingham | This is a phase II study to determine the safety and tolerability of ILB®, a type of low molecular weight dextran sulfate, in patients with Motor Neurone Disease (MND)/ Amyotrophic Lateral Sclerosis (ALS) | [
{
"type": "DRUG",
"name": "ILB®"
}
] | 2019-03-29 | https://clinicaltrials.gov/study/NCT03705390 | [
"neuroinflammation"
] | [
{
"facility": "University Hospitals Birmingham NHS Foundation Trust",
"city": "Birmingham",
"state": "West Midlands",
"country": "United Kingdom",
"status": "",
"lat": 52.48142,
"lon": -1.89983
}
] | {
"criteria": "Inclusion Criteria:\n\n1. Patients ≥18 years and who have provided written informed consent to participate in the study\n2. Prior to trial entry patients will have a definite diagnosis of ALS according to El Escorial Criteria. All patients will demonstrate either:\n\n * presence of Upper Motor Neuron... | {
"compound": "ILB® (low molecular weight dextran sulfate)",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT05286372 | An Intermediate Size Expanded Access Protocol of AMX0035 for ALS | Expanded Access | APPROVED_FOR_MARKETING | EXPANDED_ACCESS | true | Amylyx Pharmaceuticals Inc. | The Expanded Access Program will provide access and assess the safety of AMX0035 for the treatment of people living with ALS. | [
{
"type": "DRUG",
"name": "AMX0035"
}
] | https://clinicaltrials.gov/study/NCT05286372 | [
"TARDBP"
] | [
{
"facility": "University of Southern California",
"city": "Los Angeles",
"state": "California",
"country": "United States",
"status": "",
"lat": 34.05223,
"lon": -118.24368
},
{
"facility": "The Kaiser Permanente Medical Group",
"city": "Oakland",
"state": "California",
... | {
"criteria": "Inclusion Criteria:\n\n* Male or female, at least 18 years of age (inclusive);\n* Diagnosis of ALS made by a physician experienced with the management of ALS;\n* \\>36 months from symptom onset defined as first weakness\n* Capable of providing informed consent;\n* Capable of and willing to follow progr... | {
"compound": "AMX0035",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | |||
NCT04950647 | Efficacy and Safety of Nitrazine in the Treatment of ALS | PHASE2 | UNKNOWN | INTERVENTIONAL | false | Peking University Third Hospital | To evaluate the trend of safety and effectiveness of Nitroketazine tablets for ALS patients, and to explore the best effective dose. | [
{
"type": "DRUG",
"name": "Nitrofurazone Group 1"
},
{
"type": "DRUG",
"name": "Nitroketazine Group 2"
},
{
"type": "DRUG",
"name": "placebo group"
}
] | 2020-07-01 | https://clinicaltrials.gov/study/NCT04950647 | [] | [
{
"facility": "Peking University Third Hospital",
"city": "Beijing",
"state": "Beijing Municipality",
"country": "China",
"status": "RECRUITING",
"lat": 39.9075,
"lon": 116.39723
}
] | +86 13701023871 | dsfan@sina.com | {
"criteria": "Inclusion Criteria:\n\n1. Age 45-70, gender unlimited (including 45 and 70);\n2. diagnoses in accordance with the confirmed and proposed ALS diagnostic standards ofthe Revised World Federation of Neurology (1998);\n3. The duration of disease from onset to randomization of subjects is less than 2 years;... | {
"compound": "Nitroketazine",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT00573443 | Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS | PHASE3 | COMPLETED | INTERVENTIONAL | false | Avanir Pharmaceuticals | Objectives of the study are to evaluate the safety, tolerability, and efficacy of two different doses of AVP-923 (capsules containing either 30 mg of dextromethorphan hydrobromide and 10 mg of quinidine sulfate \[AVP-923-30\] or 20 mg of dextromethorphan hydrobromide and 10 mg of quinidine sulfate \[AVP-923-20\]) when ... | [
{
"type": "DRUG",
"name": "dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg"
},
{
"type": "DRUG",
"name": "dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2007-12 | https://clinicaltrials.gov/study/NCT00573443 | [
"pseudobulbar_affect"
] | [
{
"facility": "St. Joseph's Hospital and Medical Center",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "Neuromuscular Research Center",
"city": "Scottsdale",
"state": "Arizona",
"c... | {
"criteria": "Main Inclusion Criteria:\n\n* The patient has a diagnosis of Amyotrophic Lateral Sclerosis (according to El Escorial Criteria, WFN, 1998) and the time from diagnosis of ALS is not be longer than 30 months, or the patient has a diagnosis of multiple sclerosis or probable multiple sclerosis (according to... | {
"compound": "dextromethorphan hydrobromide and quinidine sulfate (AVP-923)",
"targeting_mechanism": "Dextromethorphan is an NMDA receptor antagonist that suppresses uncontrollable emotional expression (pseudobulbar affect)",
"targeting_mechanism_pmid": "28070747",
"animal_results": "unknown",
"animal_result... | ||
NCT02405403 | Microglial Activation Role In ALS (MARIA) | EARLY_PHASE1 | WITHDRAWN | INTERVENTIONAL | false | University Hospital, Tours | Neuroinflammation, characterized in particular by microglia activation, is an essential component of Amyotrophic Lateral Sclerosis (ALS) pathogenesis. Translocator Protein (TSPO) is recognized as a specific and sensitive biomarker of neuroinflammation, reflecting disease activity. An experimental radiopharmaceutical sp... | [
{
"type": "DRUG",
"name": "[18F]DPA-714 PET"
}
] | 2015-03 | https://clinicaltrials.gov/study/NCT02405403 | [
"neuroinflammation",
"TSPO"
] | [
{
"facility": "University Hospital",
"city": "Tours",
"state": "",
"country": "France",
"status": "",
"lat": 47.39484,
"lon": 0.70398
}
] | {
"criteria": "Inclusion Criteria:\n\n* Signed informed consent\n* Age ≥ 18 years old\n* Patient with probable or definite sporadic Amyotrophic Lateral Sclerosis (ALS) form according to the modified criteria of El Escorial\n* Treated with riluzole 2 weeks\n* Evolution less than 18 months\n* Mini-Mental State Examinat... | {
"compound": "[18F]DPA-714",
"targeting_mechanism": "Translocator Protein (TSPO) ligand used as a PET imaging biomarker to quantify microglial activation and neuroinflammation",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"r... | ||
NCT07095686 | Personalized Antisense Oligonucleotide for Participants With CHCHD10 ALS | PHASE1, PHASE2 | ENROLLING_BY_INVITATION | INTERVENTIONAL | false | n-Lorem Foundation | This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for individual participants with amyotrophic lateral sclerosis (ALS) due to a pathogenic variant in CHCHD10 | [
{
"type": "DRUG",
"name": "nL-CHCHD-001"
}
] | 2024-10-02 | https://clinicaltrials.gov/study/NCT07095686 | [
"CHCHD10"
] | [
{
"facility": "Columbia University, Irving Medical Center",
"city": "New York",
"state": "New York",
"country": "United States",
"status": "",
"lat": 40.71427,
"lon": -74.00597
}
] | {
"criteria": "Inclusion Criteria:\n\n* Informed consent/assent provided by the participant (when appropriate), and/or participant's parent(s) or legally authorized representatives(s)\n* Ability to travel to the study site and adhere to study related follow-up examinations and/or procedures and provide access to part... | {
"compound": "nL-CHCHD-001",
"targeting_mechanism": "Personalized antisense oligonucleotide designed to target pathogenic variants in CHCHD10 gene",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT07224256 | VOICE: An Early Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for Communication Restoration | NA | RECRUITING | INTERVENTIONAL | false | Neuralink Corp | The VOICE Study is an early feasibility study to evaluate the initial clinical safety and efficacy of the N1 and R1 Systems device design concept in providing an ability to communicate. The Neuralink N1 Implant is intended to provide the ability to communicate to individuals with severe and irreversible speech producti... | [
{
"type": "DEVICE",
"name": "N1 Implant"
},
{
"type": "DEVICE",
"name": "R1 Robot"
}
] | 2025-10-03 | https://clinicaltrials.gov/study/NCT07224256 | [] | [
{
"facility": "The University of Texas Southwestern Medical Center",
"city": "Dallas",
"state": "Texas",
"country": "United States",
"status": "RECRUITING",
"lat": 32.78306,
"lon": -96.80667
}
] | +1 (650) 250-0520 | voice-study@neuralink.com | {
"criteria": "Inclusion Criteria:\n\nAdults with diagnosis of ALS, PLS, stroke, or Spinal Cord Injury who have severe speech impairment and impaired upper limb function.\n\n* Life expectancy ≥ 12 months.\n* Ability to communicate in English\n* Presence of a stable caregiver\n\nExclusion Criteria\n\n* Moderate to hig... | {
"compound": "unknown",
"targeting_mechanism": "Brain-computer interface device intended to restore communication in individuals with severe speech impairment due to motor neuron disease",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurp... |
NCT04313166 | Treatment Continuation Study for Patients With ALS/MND Who Completed Study CMD-2019-001 | PHASE2 | COMPLETED | INTERVENTIONAL | false | Collaborative Medicinal Development Pty Limited | Provides up to six months treatment with CuATSM for subjects who have successfully completed study CMD-2019-001 | [
{
"type": "DRUG",
"name": "Cu(II)ATSM"
}
] | 2020-03-19 | https://clinicaltrials.gov/study/NCT04313166 | [
"oxidative_stress"
] | [
{
"facility": "Macquarie University",
"city": "Macquarie Park",
"state": "New South Wales",
"country": "Australia",
"status": "",
"lat": -33.78105,
"lon": 151.12757
}
] | {
"criteria": "Inclusion Criteria:\n\n* signed informed consent prior to initiation of any study-specific procedures and treatment\n* documented completion of protocol-specified assessments following completion of 24 weeks treatment on study CMD-2019-002\n* Investigator considers patient has been tolerating treatment... | {
"compound": "Cu(II)ATSM",
"targeting_mechanism": "Copper(II) complex that delivers bioavailable copper to the CNS to restore SOD1 activity and counteract oxidative stress",
"targeting_mechanism_pmid": "26826269",
"animal_results": "CuATSM treatment prevented early mortality and motor neuron degeneration in SO... | ||
NCT07509125 | Ultra-High Resolution PET in Aging, Neurodegeneration and Psychotic Disorders | NA | RECRUITING | INTERVENTIONAL | false | Universitaire Ziekenhuizen KU Leuven | The goal of this study is to use ultra-high-resolution (UHR) PET imaging to better understand how the brain and spinal cord change in healthy aging and in neurological and psychiatric disorders such as Alzheimer's disease (AD), Parkinson's disease and related movement disorders, amyotrophic lateral sclerosis (ALS), and... | [
{
"type": "OTHER",
"name": "UHR PET/CT scan of the brain with ¹⁸F-FDG"
},
{
"type": "OTHER",
"name": "UHR PET/CT scan of the brain with ¹⁸F-PE2I"
},
{
"type": "OTHER",
"name": "UHR PET/CT scan of the brain with ¹⁸F-SynVesT-1"
},
{
"type": "OTHER",
"name": "UHR PET/CT scan... | 2026-02-13 | https://clinicaltrials.gov/study/NCT07509125 | [] | [
{
"facility": "UZ Leuven",
"city": "Leuven",
"state": "Vlaams-Brabant",
"country": "Belgium",
"status": "RECRUITING",
"lat": 50.87959,
"lon": 4.70093
}
] | +32 16 34 37 11 | koen.vanlaere@uzleuven.be | {
"criteria": "Inclusion Criteria:\n\n* WP1: Healthy controls\n* Age between 18 and 90 years old (15 aged 18-50 years and 25 aged 50 90 years);\n* Subject is judged to be in good health by the investigator on the basis of medical history, physical examination including vital signs and clinical laboratory tests;\n* No... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT01759797 | Intravenous Transplantation of Mesenchymal Stem Cell in Patients With ALS | PHASE1 | COMPLETED | INTERVENTIONAL | false | Royan Institute | ALS is a debilitating disease with varied etiology characterized by rapidly progressive weakness, muscle atrophy and fasciculations, muscle spasticity, difficulty speaking (dysarthria), difficulty swallowing (dysphagia), and difficulty breathing (dyspnea). ALS is the most common of the five motor neuron diseases.Riluzo... | [
{
"type": "BIOLOGICAL",
"name": "intra venous injection of stem cell"
}
] | 2013-01 | https://clinicaltrials.gov/study/NCT01759797 | [] | [
{
"facility": "Royan Institute",
"city": "Tehran",
"state": "",
"country": "Iran",
"status": "",
"lat": 35.69439,
"lon": 51.42151
}
] | {
"criteria": "Inclusion Criteria:\n\n* \\- Age:18-65\n* both gender\n* duration of disease\\<2 years\n* FVC\\>40% ALS-FRS\\>26\n\nExclusion Criteria:\n\n* \\- neurological and psychiatric concomitant disease\n* concomitant systemic disease\n* treatment with corticosteroid,Ig,immunosuppressive during 12 months.",
"... | {
"compound": "intravenous mesenchymal stem cells",
"targeting_mechanism": "Stem cells differentiate into support cells (astrocytes, oligodendrocytes, microglia) and produce growth factors and anti-inflammatory cytokines to promote motor neuron survival and provide blood-spinal cord barrier repair.",
"targeting_m... | ||
NCT03975608 | Psychological Therapy for Patients With ALS | NA | COMPLETED | INTERVENTIONAL | false | University of Leipzig | Amyotrophic lateral sclerosis (ALS) is a disease that is inevitably fatal. To be diagnosed with a terminal illness such as ALS deeply affects one's personal existence and goes along with significant changes regarding the physical, emotional, and social domains of the patients' life. This pilot study will test a manuali... | [
{
"type": "BEHAVIORAL",
"name": "Adaptation of \"CALM\""
}
] | 2019-02-11 | https://clinicaltrials.gov/study/NCT03975608 | [] | [
{
"facility": "University Medical Center Leipzig",
"city": "Leipzig",
"state": "Saxony",
"country": "Germany",
"status": "",
"lat": 51.33962,
"lon": 12.37129
}
] | {
"criteria": "Inclusion Criteria:\n\n* confirmed diagnosis of Amyotrophic Lateral Sclerosis\n* minimum age of 18 years\n* fluent in German language\n* ability to visit the institution providing the intervention at the start of therapy (in the course of treatment, telephone-sessions may be offered)\n* ability to repo... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT05404867 | Study of Structural and Functional Brain Connectivity Changes in ALS (CoALS-II) | NA | COMPLETED | INTERVENTIONAL | false | Dartmouth-Hitchcock Medical Center | This study will try to understand the difference in brain structure between ALS patients and healthy people of similar age. ALS is a condition affecting the nervous system with disruption of the brain networks. This study aims to understand these disruptions and determine their significance in ALS. | [
{
"type": "OTHER",
"name": "fMRI"
}
] | 2022-06-08 | https://clinicaltrials.gov/study/NCT05404867 | [] | [
{
"facility": "Dartmouth-Hitchcock Medical Center",
"city": "Lebanon",
"state": "New Hampshire",
"country": "United States",
"status": "",
"lat": 43.64229,
"lon": -72.25176
}
] | {
"criteria": "Inclusion Criteria:\n\n* Based on El Escorial Criteria we will select Probable or Definite ALS.\n* Healthy controls age matched to ALS patients\n* Subjects should be able to lie down in a scanner and undergo an hour-long MRI study\n* Subjects should be able to understand instructions, provide consent a... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT05695521 | Regulatory T Cells for Amyotrophic Lateral Sclerosis | PHASE1 | ACTIVE_NOT_RECRUITING | INTERVENTIONAL | false | Cellenkos, Inc. | Phase 1 Safety Run-in Study of 6 patients followed by Phase 1b Randomized, Double Blind, Placebo Control Trial of CK0803, neurotropic, allogeneic, umbilical cord blood derived T regulatory (Treg) cells in additional 60 patients with Amyotrophic Lateral Sclerosis. | [
{
"type": "BIOLOGICAL",
"name": "CK0803"
},
{
"type": "OTHER",
"name": "Excipient"
}
] | 2023-04-03 | https://clinicaltrials.gov/study/NCT05695521 | [
"neuroinflammation"
] | [
{
"facility": "Columbia University Irving Medical Center",
"city": "New York",
"state": "New York",
"country": "United States",
"status": "",
"lat": 40.71427,
"lon": -74.00597
},
{
"facility": "Baylor College of Medicine",
"city": "Houston",
"state": "Texas",
"country... | {
"criteria": "Inclusion Criteria:\n\n* Ability of the subject or his/her legally authorized representative to provide informed consent.\n* Adult ALS subjects (≥18 years of age)\n* Diagnosis of ALS, according to the Revised El Escorial Criteria for ALS\n* Subjects with disease onset ≤ 5 years\n* Upright (sitting posi... | {
"compound": "CK0803",
"targeting_mechanism": "Allogeneic umbilical cord blood-derived T regulatory (Treg) cells that modulate neuroinflammatory responses to suppress excessive inflammatory activation in the CNS.",
"targeting_mechanism_pmid": "28872464",
"animal_results": "unknown",
"animal_results_pmid": ""... | ||
NCT05237284 | Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | TERMINATED | INTERVENTIONAL | false | Sanofi | This was a parallel treatment, Phase 2, randomized, double-blind study to assess the efficacy, safety, tolerability, PK, and PD of twice daily (BID) oral SAR443820 compared with placebo in male and female participants, 18 to 80 years of age with ALS followed by an open-label, long-term extension period.
Study ACT16970... | [
{
"type": "DRUG",
"name": "SAR443820"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2022-04-13 | https://clinicaltrials.gov/study/NCT05237284 | [
"sar443820"
] | [
{
"facility": "UC San Diego Health Site Number : 8400022",
"city": "La Jolla",
"state": "California",
"country": "United States",
"status": "",
"lat": 32.84727,
"lon": -117.2742
},
{
"facility": "USC Site Number : 8400008",
"city": "Los Angeles",
"state": "California",
... | {
"criteria": "Inclusion Criteria:\n\n* Diagnosis of possible, clinically probable ALS, clinically probable laboratory supported ALS, or clinically definite ALS according to the revised version of the El Escorial World Federation of Neurology criteria\n* Time since onset of first symptom of ALS ≤2 years.\n* Slow Vita... | {
"compound": "SAR443820",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT03986671 | Transmembrane Electromyography (TM-EMG) for the Assessment of Neuromuscular Function in the Oropharynx | NA | COMPLETED | INTERVENTIONAL | false | Powell Mansfield Inc. | This is a pilot study to examine the diagnostic utility of a novel transmembrane surface sensor, and compare signals obtained with the transmembrane sensor to conventional needle EMG signals from healthy volunteers to those with documented neurologic pharyngeal muscle dysfunction (ALS and muscular dystrophy) and to tho... | [
{
"type": "DEVICE",
"name": "Transmembrane EMG Oropharynx Probe"
}
] | 2019-04-30 | https://clinicaltrials.gov/study/NCT03986671 | [] | [
{
"facility": "SENTA Clinic",
"city": "San Diego",
"state": "California",
"country": "United States",
"status": "",
"lat": 32.71571,
"lon": -117.16472
}
] | {
"criteria": "Inclusion Criteria:\n\n* Age: 18-70\n* Must be able to pause use of anticoagulation, NSAID and multi-vitamins for appropriate period prior to study test.\n* Must be willing to stop any type of smoking or vaping 10 days prior to testing\n\nA cohort of participants with documented neurological disorders ... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT05842941 | HEALEY ALS Platform Trial - Regimen G DNL343 | PHASE2, PHASE3 | COMPLETED | INTERVENTIONAL | false | Merit E. Cudkowicz, MD | The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.
Regimen G will evaluate the safety and efficacy of a single study drug, DNL343, in participants with ALS. | [
{
"type": "DRUG",
"name": "DNL343"
},
{
"type": "DRUG",
"name": "Matching Placebo"
}
] | 2023-05-24 | https://clinicaltrials.gov/study/NCT05842941 | [
"dnl343"
] | [
{
"facility": "Healey Center for ALS at Massachusetts General Hospital",
"city": "Boston",
"state": "Massachusetts",
"country": "United States",
"status": "",
"lat": 42.35843,
"lon": -71.05977
}
] | {
"criteria": "Inclusion Criteria:\n\n* No additional inclusion criteria beyond the inclusion criteria specified in the Master Protocol (NCT NCT04297683).\n\nExclusion Criteria:\n\n* The following exclusion criteria are in addition to the exclusion criteria specified in the Master Protocol (NCT NCT04297683).\n\n 1. ... | {
"compound": "DNL343",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT02059759 | Immuno-modulation in Amyotrophic Lateral Sclerosis- a Phase II Study of Safety and Activity of Low Dose Interleukin-2 | PHASE2 | COMPLETED | INTERVENTIONAL | false | Centre Hospitalier Universitaire de Nīmes | The primary objective is to evaluate in ALS patients the regulatory T cell early response to two low-doses of IL-2 at 1 and 2 MIU per day after one course of 5 consecutive days comparatively to placebo. | [
{
"type": "DRUG",
"name": "Placebo"
},
{
"type": "DRUG",
"name": "1.0 MIU IL-2 per day"
},
{
"type": "DRUG",
"name": "2.0 MIU IL-2 per day"
}
] | 2015-09 | https://clinicaltrials.gov/study/NCT02059759 | [
"IL-2"
] | [
{
"facility": "CHRU de Montpellier - Hôpital Gui de Chauliac",
"city": "Montpellier",
"state": "",
"country": "France",
"status": "",
"lat": 43.61093,
"lon": 3.87635
}
] | {
"criteria": "Inclusion Criteria:\n\n* The patient has been correctly informed\n* The patient must have given his/her informed and signed consent.\n* The patient must be insured or beneficiary of a health insurance plan.\n* The patient is at least 18 years old and less than 75 years old\n* Probable, or laboratory-su... | {
"compound": "Interleukin-2 (IL-2)",
"targeting_mechanism": "Stimulates expansion and differentiation of regulatory T cells to modulate immune response in ALS.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": "... | ||
NCT02969759 | Bioenergetics and Protein Metabolism in Sporadic Amyotrophic Lateral Sclerosis | EARLY_PHASE1 | UNKNOWN | INTERVENTIONAL | false | University Hospital, Angers | INTRODUCTION: Amyotrophic Lateral Sclerosis (ALS) is a degenerative disease of the motor neurones of the brain and the spinal cord. The pathophysiological mechanisms of the disease remain unknown. The average age of onset of ALS is about 60 years old, and the mean survival of patients is about 2 years. The disease is r... | [
{
"type": "OTHER",
"name": "Skin Biopsy"
}
] | 2016-11 | https://clinicaltrials.gov/study/NCT02969759 | [
"bioenergetics",
"protein_metabolism"
] | [] | {
"criteria": "Inclusion criteria :\n\n* a free signed an written consent\n* aged between 18 and 80 years old\n* ALS defined by El Escorial Criteria\n* normal neurological examination\n\nExclusion criteria:\n\n* comorbidity or treatment susceptible to impact on metabolism\n* differential diagnosis suspected, early an... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT02447952 | Exploratory Study of Biotelemetry in Amyotrophic Lateral Sclerosis | NA | COMPLETED | INTERVENTIONAL | false | GlaxoSmithKline | Study 201283 is an exploratory, non-controlled, non-drug study in Amyotrophic Lateral Sclerosis (ALS) subjects. This study is being conducted as the first step for developing new meaningful measure(s) which might prove to be more effective than existing measures for monitoring clinical function and disease course in AL... | [
{
"type": "DEVICE",
"name": "Faros Sensor (FS) and LifeInsight Hub"
},
{
"type": "DEVICE",
"name": "Fast Fix electrode patch"
},
{
"type": "PROCEDURE",
"name": "Quantitative Measure of Speech (Core Phase Only)"
}
] | 2015-06-30 | https://clinicaltrials.gov/study/NCT02447952 | [] | [
{
"facility": "GSK Investigational Site",
"city": "London",
"state": "",
"country": "United Kingdom",
"status": "",
"lat": 51.50853,
"lon": -0.12574
},
{
"facility": "GSK Investigational Site",
"city": "Oxford",
"state": "",
"country": "United Kingdom",
"status": ... | {
"criteria": "Inclusion Criteria:\n\n* Between 18 and 80 years of age, inclusive, at the time of signing the informed consent.\n* Diagnosed with ALS by a neurologist with expertise in ALS. For subjects with bulbar onset there must be objective limb involvement of at least one limb.\n* Diagnosed with ALS within 18 mo... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT01123148 | A P300 Brain Computer Interface to Operate Power Wheelchair Tilt | NA | COMPLETED | INTERVENTIONAL | false | University of Michigan | The investigators want to develop a brain-computer interface (BCI) that will eventually allow people who are completely paralyzed to independently control the tilt feature on their power wheelchairs. This study will allow healthy volunteers to test the feasibility and accuracy of controlling a BCI using only their brai... | [
{
"type": "DEVICE",
"name": "Using a BCI to control wheelchair tilt"
}
] | 2010-01 | https://clinicaltrials.gov/study/NCT01123148 | [] | [] | {
"criteria": "Inclusion Criteria:\n\n* Age 18 or older.\n* Able to read text on a computer screen\n* Able to understand and remember instructions concerning participation.\n\nExclusion Criteria:\n\n* Unable give informed consent.\n* Unable to understand and follow instructions.\n* Have abnormal tone or uncontrolled ... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT04562831 | The NO-ALS Study: A Trial of Nicotinamide/Pterostilbene Supplement in ALS. | NA | ACTIVE_NOT_RECRUITING | INTERVENTIONAL | false | Haukeland University Hospital | Amyotrophic lateral sclerosis (ALS) is a serious rapidly progressive disease of the nervous system. The average survival from the time of diagnosis is 3 years. Apart from Riluzole, there is no effective treatment. Care of advanced ALS will have a cost of 4-8 million NOK per year
Research i.a. from the investigators de... | [
{
"type": "DIETARY_SUPPLEMENT",
"name": "EH301 (Nicotinamide Riboside/Pterostilbene)"
}
] | 2020-10-07 | https://clinicaltrials.gov/study/NCT04562831 | [
"Histone deacetylases"
] | [
{
"facility": "Haukeland University Hospital",
"city": "Bergen",
"state": "",
"country": "Norway",
"status": "",
"lat": 60.39299,
"lon": 5.32415
},
{
"facility": "Vestre Viken HF",
"city": "Drammen",
"state": "",
"country": "Norway",
"status": "",
"lat": 59.74... | {
"criteria": "Inclusion Criteria:\n\nArm 1 (newly diagnosed ALS patients)\n\n* Have a clinical diagnosis of probable ALS according to the revised El Escorial criteria.\n* MR of the brain and cervical spine cannot explain symptoms.\n* Diagnosed with likely ALS within 6 months from enrolment and treated with Riluzole ... | {
"compound": "EH301 (Nicotinamide Riboside/Pterostilbene)",
"targeting_mechanism": "Increases NAD availability and sirtuin activity to enhance histone deacetylation and delay disease progression.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "u... | ||
NCT00886977 | Efficacy and Safety of YAM80 in Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | UNKNOWN | INTERVENTIONAL | false | Yoshino Neurology Clinic | The efficacy and safety are evaluated when YAM80 is administered orally to the patients of Amyotrophic Lateral Sclerosis (ALS). | [
{
"type": "DRUG",
"name": "YAM80"
}
] | 2009-04 | https://clinicaltrials.gov/study/NCT00886977 | [
"yam80"
] | [
{
"facility": "Yoshino Neurology Clinic",
"city": "Tokyo",
"state": "",
"country": "Japan",
"status": "",
"lat": 35.6895,
"lon": 139.69171
}
] | {
"criteria": "Inclusion Criteria:\n\n* Patients aged between 25 and 65 years\n* ALS patients who can visit the clinic for six months\n* Forced Vital Capacity (FVC) \\> 70%\n* Patients who can walk by themselves\n* Change in ALSFRS-R score from -1 to -4 during 12 weeks before the initial administration\n* Patients wh... | {
"compound": "YAM80",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT06726577 | TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis | PHASE1, PHASE2 | RECRUITING | INTERVENTIONAL | false | Talengen Institute of Life Sciences, Shenzhen, P.R. China. | This trial adopts a multicenter, randomized, double-blind, placebo-controlled parallel design.
This experiment is divided into two groups: the experimental drug group and the placebo group. Successful participants will be randomly assigned to the two groups, with an expected enrollment of 60 participants. There will b... | [
{
"type": "DRUG",
"name": "TP04HN106"
},
{
"type": "DRUG",
"name": "Saline"
}
] | 2026-05-10 | https://clinicaltrials.gov/study/NCT06726577 | [
"tp04hn106"
] | [
{
"facility": "The First Affiliated Hospital of Soochow University",
"city": "Suzhou",
"state": "Jiangsu",
"country": "China",
"status": "RECRUITING",
"lat": 31.30408,
"lon": 120.59538
}
] | 0086-89290018 | jnl@talengen-pharma.com | {
"criteria": "Inclusion Criteria:\n\n1. Meet the diagnostic criteria for amyotrophic lateral sclerosis (ALS) (Gold Coast Criteria 2020）;\n2. Age ≥18 years old, male or female;\n3. The amyotrophic lateral sclerosis Function Rating Scale (ALSFRS-R）of pre-visit subjects should be ≥1 score for dyspnea, upright breathing... | {
"compound": "TP04HN106",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.